Combination of beta-lactam compound and probenecid and application thereof

By co-administering β-lactam compounds with probenecid, the same administration route was adopted to improve the plasma concentration and retention time of β-lactam compounds, and the plasma concentration of β-lactam antibiotics was solved when treating bacterial infections. Maintenance difficulties and problems arising from resistance enhance the therapeutic effect.

CN118903120APending Publication Date: 2024-11-08ITERUM THERAPEUTICS INT LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410957648.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-02-13
Filing Date
2019-06-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing beta-lactam antibiotics are difficult to maintain effective plasma concentrations and avoid the problems of antibacterial resistance when treating bacterial infections.

Method used

By co-administering the beta-lactam compound with probenecid, the same route of administration, such as oral administration, is used to increase the plasma concentration of the beta-lactam compound and prolong its retention time in vivo.

Benefits of technology

The area under the plasma curve (AUC) and maximum plasma concentration (Cmax) of β-lactam compounds are significantly improved, thereby enhancing the inhibitory effect on bacteria and reducing the risk of resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004949333330000411
    Figure BDA0004949333330000411
  • Figure BDA0004949333330000412
    Figure BDA0004949333330000412
  • Figure BDA0004949333330000413
    Figure BDA0004949333330000413
Patent Text Reader

Abstract

The present disclosure relates to a combination of a beta-lactam compound or a pharmaceutically acceptable salt thereof with probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to a subject in need thereof a beta-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Application No. 62 / 804,970, filed on February 13, 2019, and U.S. Provisional Application No. 62 / 682,116, filed on June 7, 2018, the entire contents of which are incorporated herein by reference. background β-lactam compounds are a class of antibiotics that have a β-lactam ring in their molecular structure. β-lactam compounds have been used to treat diseases associated with both Gram-positive and Gram-negative bacteria. The mechanism of action of these β-lactam compounds preferably requires that the concentration of the antibiotic be maintained at or above a certain inhibitory threshold, referred to as the "mean inhibitory concentration (MIC)", in order to be effective. Maintaining elevated concentrations of these antibiotics also helps to avoid the possibility of antimicrobial resistance due to selection of bacteria with higher MICs. Therefore, there is a need for compositions and methods related to β-lactam antibiotics that optimize their tissue concentrations to improve their ability to control infection and to mitigate or eliminate the possibility of antibiotic resistance.

[0003] Overview The present disclosure particularly provides a method for treating or preventing a disease, the method comprising administering a pharmaceutically effective amount of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered by the same administration route.

[0004] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered simultaneously.

[0005] In some embodiments, both the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered by enteral administration.

[0006] In some embodiments, the enteral administration is oral administration.

[0007] In some embodiments, an oral co-formulation comprising the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof is administered.

[0008] In some embodiments, the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, are both administered in separate oral formulations.

[0009] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration.

[0010] In some embodiments, the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) are basically the same.

[0011] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to comparable subjects administered said beta-lactam compound and probenecid by a different route of administration; and The maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof is substantially the same as that of a comparable subject given the β-lactam compound and probenecid by a different route of administration. max ).

[0012] In some aspects, the present disclosure provides a method of treating or preventing a disease, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0013] In some aspects, the present disclosure provides a β-lactam compound or a pharmaceutically acceptable salt thereof, in combination with probenecid or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0014] In some aspects, the present disclosure provides probenecid or a pharmaceutically acceptable salt thereof, in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0015] In some aspects, the present disclosure provides a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0016] In some aspects, the present disclosure provides use of a β-lactam compound in combination with probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0017] In some aspects, the present disclosure provides use of probenecid in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0018] In some aspects, the present disclosure provides use of a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0019] In some aspects, the present disclosure provides a β-lactam compound or a pharmaceutically acceptable salt thereof, in combination with probenecid or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease, wherein: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0020] In some aspects, the present disclosure provides probenecid or a pharmaceutically acceptable salt thereof, in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease, wherein: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0021] In some aspects, the present disclosure provides a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease, wherein: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0022] In some aspects, the present disclosure provides use of a β-lactam compound or a pharmaceutically acceptable salt thereof in combination with probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease, wherein administration of the medicament to a subject in need thereof over a period of time results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0023] In some aspects, the present disclosure provides the use of probenecid or a pharmaceutically acceptable salt thereof in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease, wherein administration of the medicament to a subject in need thereof over a period of time results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0024] In some aspects, the present disclosure provides a use of a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease, wherein administration of the medicament to a subject in need thereof over a period of time results in a plasma concentration of the β-lactam compound having: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof during the time period compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0025] In some aspects, the present disclosure provides a pharmaceutical composition comprising a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

[0026] In some aspects, the present disclosure provides a pharmaceutical kit comprising a β-lactam compound or a pharmaceutically acceptable salt thereof in a first package and probenecid or a pharmaceutically acceptable salt thereof in a second package.

[0027] In some aspects, the present disclosure provides a compound or a pharmaceutical salt thereof, wherein administration of the compound or a pharmaceutical salt thereof in combination with probenecid or a pharmaceutically acceptable salt thereof in a subject in need thereof over a period of time results in a plasma concentration versus time profile of the compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said compound without administration of probenecid over said time period, A higher maximum plasma concentration (C ) of the compound in the subject in need thereof during the time period as compared to the comparable subject administered the pharmaceutically effective amount of the compound without probenecid. max ),or Its combination.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. In this specification, the singular also includes the plural, unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference. The references cited herein are not recognized as prior art of the claimed invention. In the event of a conflict, this specification (including definitions) shall prevail. In addition, materials, methods and examples are illustrative only, not restrictive. In the event of a conflict between the chemical structure and the name of the compound disclosed herein, the chemical structure shall prevail.

[0029] Other features and advantages of the disclosure will be apparent from the following detailed description, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS The patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication with one or more color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0031] Figure 1is a graph showing the effect of probenecid on the area under the curve (AUC) of sulopenem in plasma when delivered with an oral sulopenem prodrug by the oral route.

[0032] Figure 2 It is a graph showing the effects of administration of a β-lactam compound (Compound III-2b) and probenecid on the plasma level of a β-lactam compound (Compound IIb) in the fasting state.

[0033] Figure 3 It is a graph showing the effects of administration of a β-lactam compound (Compound III-2b) and probenecid on the plasma level of a β-lactam compound (Compound IIb) in the fed state.

[0034] Figure 4 is a graph showing the effect of administration of a β-lactam compound (Compound III-2b) and probenecid by the same route of administration (compared to administration by different routes of administration) on the area under the curve (AUC) of a β-lactam compound (Compound IIb).

[0035] Figure 5 The maximum plasma concentration (C max )’s effect. Detailed Description The present disclosure particularly provides a method for treating or preventing a disease, the method comprising administering a pharmaceutically effective amount of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered by the same administration route.

[0037] In some aspects, the present disclosure provides a method of treating or preventing a disease, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0038] In some embodiments, the period of time is longer than about 24 hours.

[0039] In some embodiments, the time period ranges from about 2 days to about 30 days, about 3 days to about 20 days, about 4 days to about 15 days, about 5 days to about 10 days, or about 6 days to about 8 days.

[0040] In some embodiments, the period of time is about 7 days.

[0041] For AUC and / or C max Role In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration.

[0042] In some embodiments, the administration results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration.

[0043] In some embodiments, the administration results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 10% or more, about 15% or more, about 20% or more, about 25% or more, or about 30% or more within about 12 hours, about 18 hours, about 1 day, about 2 days, or about 3 days from the administration.

[0044] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 15% or more, about 20% or more, or about 25% or more within about 18 hours, about 1 day, or about 2 days from the administering.

[0045] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 15% or more, about 20% or more, or about 25% or more within about 18 hours from the administering.

[0046] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 15% or more, about 20% or more, or about 25% or more, within about 1 day from the administering.

[0047] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 15% or more, about 20% or more, or about 25% or more within about 2 days from the administering.

[0048] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, wherein the area under the curve is about 20% or more higher within about 1 day from the administering.

[0049] In some embodiments, the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) is from about 50% to about 150%, from about 60% to about 140%, from about 70% to about 130%, from about 80% to about 120%, from about 90% to about 110%, from about 95% to about 105%, or from 98% to about 102%.

[0050] In some embodiments, the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) is from about 70% to about 130%, from about 80% to about 120%, from about 90% to about 110%, from about 95% to about 105%, or from 98% to about 102%.

[0051] In some embodiments, the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) is from about 90% to about 110%, from about 95% to about 105%, or from 98% to about 102%.

[0052] In some embodiments, the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) is from about 95% to about 105%, or from 98% to about 102%.

[0053] In some embodiments, the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) is from 98% to about 102%.

[0054] In some embodiments, administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) are basically the same.

[0055] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to comparable subjects administered said beta-lactam compound and probenecid by a different route of administration; and Substantially the same maximum plasma concentration (C ) in the subject in need thereof compared to comparable subjects administered the β-lactam compound and probenecid by a different route of administration. max ).

[0056] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: A higher area under the curve (AUC) in the subject in need thereof compared to a comparable subject administered the beta-lactam compound and probenecid by a different route of administration, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration.

[0057] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in the subject in need thereof, compared to a comparable subject administered the beta-lactam compound and probenecid by a different route of administration, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration; The maximum plasma concentration (C max ) is from about 50% to about 150%, from about 60% to about 140%, from about 70% to about 130%, from about 80% to about 120%, from about 90% to about 110%, from about 95% to about 105%, or from 98% to about 102%.

[0058] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in the subject in need thereof, compared to a comparable subject administered the beta-lactam compound and probenecid by a different route of administration, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration; Substantially the same maximum plasma concentration (C ) in the subject in need thereof compared to comparable subjects administered the β-lactam compound and probenecid by a different route of administration. max ).

[0059] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: A higher area under the curve (AUC) in the subject in need thereof, compared to comparable subjects administered the β-lactam compound and probenecid in separate formulations, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration.

[0060] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in the subject in need thereof, compared to comparable subjects administered the beta-lactam compound and probenecid in separate formulations, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration; The maximum plasma concentration (C max ) is from about 50% to about 150%, from about 60% to about 140%, from about 70% to about 130%, from about 80% to about 120%, from about 90% to about 110%, from about 95% to about 105%, or from 98% to about 102%.

[0061] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in the subject in need thereof, compared to comparable subjects administered the beta-lactam compound and probenecid in separate formulations, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration; Substantially the same maximum plasma concentration (C ) in said subject in need thereof as compared to comparable subjects administered said β-lactam compound and probenecid in separate formulations max ).

[0062] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: A higher area under the curve (AUC) in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., a comparable subject fasting), the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration.

[0063] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in the subject in need thereof, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration, as compared to a comparable subject administered the beta-lactam compound and probenecid without food (e.g., the comparable subject is fasting); and The maximum plasma concentration (C max ) is from about 50% to about 150%, from about 60% to about 140%, from about 70% to about 130%, from about 80% to about 120%, from about 90% to about 110%, from about 95% to about 105%, or from 98% to about 102%.

[0064] In some embodiments, the administering results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in the subject in need thereof, the area under the curve being about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 80% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration, as compared to a comparable subject administered the beta-lactam compound and probenecid without food (e.g., the comparable subject is fasting); and Substantially the same maximum plasma concentration (C ) in the subject in need thereof as compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., a comparable subject fasting). max ).

[0065] In some embodiments, about 500±400 mg, about 500±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of a β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg of the β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg of the β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof are added. mg, about 500±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of probenecid or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof by the same route of administration, and the administration results in a plasma concentration of the β-lactam compound having: Within about 1 day from the administration, about 4325±3000ng·h / mL, about 4325±2500ng·h / mL, about 4325±2000ng·h / mL, about 4325±1500ng·h / mL, about 4325±1000ng·h / mL, about 4325±900ng·h / mL, about 4325±800ng·h / mL, about 4325±700ng·h / mL, about 4325±600ng·h / mL, about 4325±500ng·h / mL, about 4325±400ng·h / mL, about 4325±300ng·h / mL g·h / mL, about 4325±200 ng·h / mL, about 4325±100 ng·h / mL, about 4325±90 ng·h / mL, about 4325±80 ng·h / mL, about 4325±70 ng·h / mL, about 4325±60 ng·h / mL, about 4325±50 ng·h / mL, about 4325±40 ng·h / mL, about 4325±30 ng·h / mL, about 4325±20 ng·h / mL, or about 4325±10 ng·h / mL (e.g., about 4325 ng·h / mL).

[0066] In some embodiments, about 500±400 mg, about 500±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of a β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg, about 500±300 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of a β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg, about 500±300 mg, about 500±300 mg 00 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of probenecid or a pharmaceutically acceptable salt thereof is administered to the subject in need thereof (e.g., the subject eats) by the same route of administration and with food, and the administration results in a plasma concentration of the β-lactam compound having: Within about 1 day from the administration, about 6600±3000ng·h / mL, about 6600±2500ng·h / mL, about 6600±2000ng·h / mL, about 6600±1500ng·h / mL, about 6600±1000ng·h / mL, about 6600±900ng·h / mL, about 6600±800ng·h / mL, about 6600±700ng·h / mL, about 6600±600ng·h / mL, about 6600±500ng·h / mL, about 6600±400ng·h / mL, about 6600±300ng·h / mL. g·h / mL, about 6600±200 ng·h / mL, about 6600±100 ng·h / mL, about 6600±90 ng·h / mL, about 6600±80 ng·h / mL, about 6600±70 ng·h / mL, about 6600±60 ng·h / mL, about 6600±50 ng·h / mL, about 6600±40 ng·h / mL, about 6600±30 ng·h / mL, about 6600±20 ng·h / mL, or about 6600±10 ng·h / mL (e.g., about 6600 ng·h / mL).

[0067] In some embodiments, about 500±400 mg, about 500±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of a β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg, about 500±30 ... about 500±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of probenecid or a pharmaceutically acceptable salt thereof in a co-formulation is administered to the subject in need thereof, and the administration results in a plasma concentration of the β-lactam compound having: Within about 1 day from the administration, about 5100±3000ng·h / mL, about 5100±2500ng·h / mL, about 5100±2000ng·h / mL, about 5100±1500ng·h / mL, about 5100±1000ng·h / mL, about 5100±900ng·h / mL, about 5100±800ng·h / mL, about 5100±700ng·h / mL, about 5100±600ng·h / mL, about 5100±500ng·h / mL, about 5100±400ng·h / mL, about 5100±300ng·h / mL. g·h / mL, about 5100±200 ng·h / mL, about 5100±100 ng·h / mL, about 5100±90 ng·h / mL, about 5100±80 ng·h / mL, about 5100±70 ng·h / mL, about 5100±60 ng·h / mL, about 5100±50 ng·h / mL, about 5100±40 ng·h / mL, about 5100±30 ng·h / mL, about 5100±20 ng·h / mL, or about 5100±10 ng·h / mL (e.g., about 5100 ng·h / mL).

[0068] In some embodiments, about 500±400 mg, about 500±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of a β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg, about 500±50 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of a β-lactam compound (e.g., Compound III-2b) or a pharmaceutically acceptable salt thereof and about 500±400 mg, about 500±50 mg ±300 mg, about 500±200 mg, about 500±100 mg, about 500±90 mg, about 500±80 mg, about 500±70 mg, about 500±60 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, or about 500±5 mg (e.g., about 500 mg) of probenecid or a pharmaceutically acceptable salt thereof in a co-formulation and administered with food to the subject in need thereof (e.g., the subject eats), and the administration results in a plasma concentration of the β-lactam compound having: Within about 1 day from the administration, about 7340±3000ng·h / mL, about 7340±2500ng·h / mL, about 7340±2000ng·h / mL, about 7340±1500ng·h / mL, about 7340±1000ng·h / mL, about 7340±900ng·h / mL, about 7340±800ng·h / mL, about 7340±700ng·h / mL, about 7340±600ng·h / mL, about 7340±500ng·h / mL, about 7340±400ng·h / mL, about 7340±300ng·h / mL. g·h / mL, about 7340±200 ng·h / mL, about 7340±100 ng·h / mL, about 7340±90 ng·h / mL, about 7340±80 ng·h / mL, about 7340±70 ng·h / mL, about 7340±60 ng·h / mL, about 7340±50 ng·h / mL, about 7340±40 ng·h / mL, about 7340±30 ng·h / mL, about 7340±20 ng·h / mL, or about 7340±10 ng·h / mL (e.g., about 7340 ng·h / mL).

[0069] In some embodiments, about 500 mg of the β-lactam compound or the pharmaceutically acceptable salt and about 500 mg of probenecid or the pharmaceutically acceptable salt are administered to the subject in need thereof, and the administration results in a plasma concentration of the β-lactam compound having: Within about 12 hours from the administration, about 4100 ng·h / mL to about 5500 ng·h / mL, about 4200 ng·h / mL to about 5400 ng·h / mL, about 4300 ng·h / mL to about 5300 ng·h / mL, about 4400 ng·h / mL to about 5200 ng·h / mL, about 4500 ng·h / mL to about 5100 ng·h / mL, about 4650 ng·h / mL to about 5000 ng·h / mL, about 4750 ng·h / mL to about 4900 ng·h / mL, or about 4800 ng·h / mL to about 5 and a maximum plasma concentration (C ) of about 1100 ng / mL to about 2500 ng / mL, about 1200 ng / mL to about 2400 ng / mL, about 1300 ng / mL to about 2300 ng / mL, about 1400 ng / mL to about 2200 ng / mL, about 1500 ng / mL to about 2100 ng / mL, about 1650 ng / mL to about 2000 ng / mL, about 1750 ng / mL to about 1900 ng / mL, or about 1800 ng / mL to about 1850 ng / mL. max ).

[0070] In some embodiments, about 500 mg of the β-lactam compound or the pharmaceutically acceptable salt and about 500 mg of probenecid or the pharmaceutically acceptable salt are administered to the subject in need thereof, and the administration results in a plasma concentration of the β-lactam compound having: an area under the curve (AUC) of about 7000 ng·h / mL to about 8400 ng·h / mL, about 7100 ng·h / mL to about 8300 ng·h / mL, about 7200 ng·h / mL to about 8200 ng·h / mL, about 7300 ng·h / mL to about 5100 ng·h / mL, about 7450 ng·h / mL to about 8100 ng·h / mL, about 7500 ng·h / mL to about 8050 ng·h / mL, or about 7550 ng·h / mL to about 8000 ng·h / mL within about 12 hours from said administration; and The maximum plasma concentration (C) is about 2100 ng / mL to about 3300 ng / mL, about 2200 ng / mL to about 3200 ng / mL, about 2300 ng / mL to about 3100 ng / mL, about 2400 ng / mL to about 3000 ng / mL, about 2500 ng / mL to about 2900 ng / mL, about 2550 ng / mL to about 2800 ng / mL, about 2600 ng / mL to about 2750 ng / mL, or about 2650 ng / mL to about 2700 ng / mL. max ).

[0071] In some embodiments, the administering results in a higher area under the curve (AUC) for plasma concentration of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., a comparable subject fasting).

[0072] In some embodiments, the administration results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., a comparable subject fasting), the area under the curve being about 5% or more, about 10% or more, about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 100% or more, about 150% or more, about 200% or more, about 300% or more, about 400% or more, or about 500% or more within about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days from the administration.

[0073] In some embodiments, the administration results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., a comparable subject fasting), the area under the curve being about 50% or more, about 55% or more, about 60% or more, about 65% or more, or about 70% or more within about 12 hours, about 18 hours, about 1 day, about 2 days, or about 3 days from the administration.

[0074] In some embodiments, the administering results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., the comparable subject is fasting), the area under the curve being about 55% or more, about 60% or more, or about 65% or more within about 12 hours, about 1 day, or about 2 days from the administering.

[0075] In some embodiments, the administering results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., the comparable subject is fasting), the area under the curve being about 55% or more, about 60% or more, or about 65% or more within about 12 hours from the administering.

[0076] In some embodiments, the administering results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., the comparable subject is fasting), the area under the curve being about 55% or more, about 60% or more, or about 65% or more within about 1 day from the administering.

[0077] In some embodiments, the administering results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., the comparable subject is fasting), the area under the curve being about 55% or more, about 60% or more, or about 65% or more at about 2 days from the administering.

[0078] In some embodiments, the administering results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof, compared to a comparable subject administered the β-lactam compound and probenecid without food (e.g., the comparable subject is fasting), wherein the area under the curve is about 60% or more higher within about 1 day from the administering.

[0079] In some embodiments, at a time after about the first 24 hours of said administration, the AUC and C of the plasma concentration of said β-lactam compound in said subject in need thereof are observed. max One or both of .

[0080] In some embodiments, the AUC and C of the plasma concentration of the β-lactam compound in the subject in need thereof are observed within about the first 2 days after the administration and within about the first 30 days, within about the first 3 days after the administration and within about the first 20 days, within about the first 4 days after the administration and within about the first 15 days, within about the first 5 days after the administration and within about the first 10 days, or within about the first 6 days after the administration and within about the first 8 days. max One or both of .

[0081] In some embodiments, at about day 7 of the administration, the AUC and C of the plasma concentration of the β-lactam compound in the subject in need thereof are observed. max One or both of .

[0082] In some embodiments, the AUC and C of the plasma concentration of the β-lactam compound in the subject in need thereof are observed after about the first 24 hours of the administration and at or before about day 30, about day 20, about day 15, about day 10, about day 8, or about day 7 of the administration. max One or both of .

[0083] In some embodiments, the AUC and C of the plasma concentration of the β-lactam compound in the comparable subjects at the end of the time period are compared to the first day of administration. max One or both are lower, preferably an amount ranging from about 1% to about 60%, about 3% to about 50%, about 5% to about 40%, about 8% to about 38%, or about 10% to about 35%.

[0084] In some embodiments, the AUC and C of the plasma concentration of the β-lactam compound in the subject in need thereof at the end of the time period are compared to the comparable subject on the first day of the dosing. max One or both of the above are higher, preferably an amount in the range of about 2% to about 100%, about 4% to about 80%, about 6% to about 60%, about 8% to about 40%, about 10% to about 30%, about 12% to about 25%, or about 15% to about 20%.

[0085] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max In the range of about 1.5 ng / mL to about 2.5 ng / mL, about 1.6 ng / mL to about 2.4 ng / mL, about 1.7 ng / mL to about 2.3 ng / mL, about 1.8 ng / mL to about 2.2 ng / mL, or about 1.9 ng / mL to about 2.1 ng / mL per mg of β-lactam compound administered daily.

[0086] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max This is approximately 2.0 ng / mL per mg of β-lactam compound administered daily.

[0087] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C maxIn the range of about 0.7 ng / mL to about 1.8 ng / mL, about 0.8 ng / mL to about 1.7 ng / mL, about 0.9 ng / mL to about 1.6 ng / mL, about 1.0 ng / mL to about 1.5 ng / mL, about 1.1 ng / mL to about 1.4 ng / mL, or about 1.2 ng / mL to about 1.3 ng / mL per mg of β-lactam compound administered daily.

[0088] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C max This is approximately 1.25 ng / mL per mg of β-lactam compound administered daily.

[0089] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max In the range of about 1.6 ng / mL to about 2.7 ng / mL, about 1.7 ng / mL to about 2.6 ng / mL, about 1.8 ng / mL to about 2.5 ng / mL, about 1.9 ng / mL to about 2.4 ng / mL, about 2.0 ng / mL to about 2.3 ng / mL, or about 2.1 ng / mL to about 2.2 ng / mL per mg of β-lactam compound administered daily.

[0090] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max This is approximately 2.15 ng / mL per mg of β-lactam compound administered daily.

[0091] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max In the range of about 1.6 ng / mL to about 2.7 ng / mL, about 1.7 ng / mL to about 2.6 ng / mL, about 1.8 ng / mL to about 2.5 ng / mL, about 1.9 ng / mL to about 2.4 ng / mL, about 2.0 ng / mL to about 2.3 ng / mL, or about 2.1 ng / mL to about 2.2 ng / mL per mg of β-lactam compound administered daily.

[0092] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max This is approximately 2.15 ng / mL per mg of β-lactam compound administered daily.

[0093] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max In the range of about 1.2 ng / mL to about 2.2 ng / mL, about 1.3 ng / mL to about 2.1 ng / mL, about 1.4 ng / mL to about 2.0 ng / mL, about 1.5 ng / mL to about 1.9 ng / mL, or about 1.6 ng / mL to about 1.8 ng / mL per mg of β-lactam compound administered daily.

[0094] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max This is approximately 1.7 ng / mL per mg of β-lactam compound administered daily.

[0095] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C max In the range of about 0.8 ng / mL to about 1.8 ng / mL, about 0.9 ng / mL to about 1.7 ng / mL, about 1.0 ng / mL to about 1.6 ng / mL, about 1.1 ng / mL to about 1.5 ng / mL, or about 1.2 ng / mL to about 1.4 ng / mL per mg of β-lactam compound administered daily.

[0096] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C max This is approximately 1.3 ng / mL per mg of β-lactam compound administered daily.

[0097] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max In the range of about 1.2 ng / mL to about 2.2 ng / mL, about 1.3 ng / mL to about 2.1 ng / mL, about 1.4 ng / mL to about 2.0 ng / mL, about 1.5 ng / mL to about 1.9 ng / mL, or about 1.6 ng / mL to about 1.8 ng / mL per mg of β-lactam compound administered daily.

[0098] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max This is approximately 1.7 ng / mL per mg of β-lactam compound administered daily.

[0099] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max In the range of about 0.9 ng / mL to about 2.0 ng / mL, about 1.0 ng / mL to about 1.9 ng / mL, about 1.1 ng / mL to about 1.8 ng / mL, about 1.2 ng / mL to about 1.7 ng / mL, about 1.3 ng / mL to about 1.6 ng / mL, or about 1.4 ng / mL to about 1.5 ng / mL per mg of β-lactam compound administered daily.

[0100] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max This is approximately 1.45 ng / mL per mg of β-lactam compound administered daily.

[0101] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on the first day of the administration is from about 2.5 hr*ng / mL to about 3.2 hr*ng / mL, from about 2.6 hr*ng / mL to about 3.1 hr*ng / mL, from about 2.7 hr*ng / mL to about 3.0 hr*ng / mL, or from about 2.8 hr*ng / mL to about 2.9 hr*ng / mL per mg of the β-lactam compound administered daily.

[0102] In some embodiments, the plasma concentration of the β-lactam compound achieved in the comparable subject on the first day of the administration has an AUC of about 2.85 hr*ng / mL per mg of the β-lactam compound administered daily.

[0103] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the dosing is within the range of about 1.6 hr*ng / mL to about 2.2 hr*ng / mL, about 1.7 hr*ng / mL to about 2.1 hr*ng / mL, or about 1.8 hr*ng / mL to about 2.0 hr*ng / mL per mg of the β-lactam compound administered daily.

[0104] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on day 7 of the dosing has an AUC of about 1.9 hr*ng / mL per mg of the β-lactam compound administered daily.

[0105] In some embodiments, the AUC of the plasma concentration of the β-lactam compound achieved in the subject in need thereof on the first day of the administration is within the range of about 3.9 hr*ng / mL to about 4.5 hr*ng / mL, about 4.0 hr*ng / mL to about 4.4 hr*ng / mL, or about 4.1 hr*ng / mL to about 4.3 hr*ng / mL per mg of the β-lactam compound administered daily.

[0106] In some embodiments, the plasma concentration of the β-lactam compound achieved in the subject in need thereof on the first day of the administration has an AUC of about 4.2 hr*ng / mL per mg of β-lactam compound administered daily.

[0107] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing is within the range of about 4.1 hr*ng / mL to about 4.7 hr*ng / mL, about 4.2 hr*ng / mL to about 4.6 hr*ng / mL, or about 4.3 hr*ng / mL to about 4.5 hr*ng / mL per mg of β-lactam compound administered daily.

[0108] In some embodiments, the plasma concentration of the β-lactam compound achieved in the subject in need thereof on day 7 of the dosing has an AUC of about 4.4 hr*ng / mL per mg of β-lactam compound administered daily.

[0109] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on the first day of said dosing is within the range of about 3.2 hr*ng / mL to about 4.0 hr*ng / mL, about 3.3 hr*ng / mL to about 3.9 hr*ng / mL, about 3.4 hr*ng / mL to about 3.8 hr*ng / mL, or about 3.5 hr*ng / mL to about 3.7 hr*ng / mL per mg of β-lactam compound administered daily.

[0110] In some embodiments, the plasma concentration of the β-lactam compound achieved in the comparable subject on the first day of the administration has an AUC of about 3.6 hr*ng / mL per mg of the β-lactam compound administered daily.

[0111] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the dosing is within the range of about 2.2 hr*ng / mL to about 3.1 hr*ng / mL, about 2.3 hr*ng / mL to about 3.0 hr*ng / mL, about 2.4 hr*ng / mL to about 2.9 hr*ng / mL, about 2.5 hr*ng / mL to about 2.8 hr*ng / mL, or about 2.6 hr*ng / mL to about 2.7 hr*ng / mL per mg of the β-lactam compound administered daily.

[0112] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on day 7 of the dosing has an AUC of about 2.65 hr*ng / mL per mg of the β-lactam compound administered daily.

[0113] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the dosing is within the range of about 3.4 hr*ng / mL to about 4.3 hr*ng / mL, about 3.5 hr*ng / mL to about 4.2 hr*ng / mL, about 3.6 hr*ng / mL to about 4.1 hr*ng / mL, about 3.7 hr*ng / mL to about 4.0 hr*ng / mL, or about 3.8 hr*ng / mL to about 3.9 hr*ng / mL per mg of β-lactam compound administered daily.

[0114] In some embodiments, the plasma concentration of the β-lactam compound achieved in the subject in need thereof on the first day of the administration has an AUC of about 3.85 hr*ng / mL per mg of β-lactam compound administered daily.

[0115] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing is within the range of about 3.9 hr*ng / mL to about 4.7 hr*ng / mL, about 4.0 hr*ng / mL to about 4.6 hr*ng / mL, about 4.1 hr*ng / mL to about 4.4 hr*ng / mL, about 4.2 hr*ng / mL to about 4.3 hr*ng / mL per mg of β-lactam compound administered daily.

[0116] In some embodiments, the plasma concentration of the β-lactam compound achieved in the subject in need thereof on day 7 of the dosing has an AUC of about 4.25 hr*ng / mL per mg of β-lactam compound administered daily.

[0117] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C maxFor each mg of β-lactam compound administered daily, about 0.5 ng / mL, about 0.55 ng / mL, about 0.6 ng / mL, about 0.65 ng / mL, about 0.7 ng / mL, about 0.75 ng / mL, about 0.8 ng / mL, about 0.85 ng / mL, about 0.9 ng / mL, about 0.95 ng / mL, about 1 ng / mL, about 1.05 ng / mL, about 1.1 ng / mL, about 1.15 ng / mL, about 1.2 ng / mL, about 1.25 ng / mL, about 1.3 ng / mL, about 1.35 ng / mL, about 1.4 ng / mL, about 1.45 ng / mL, about 1.5 ng / mL, about 1.55 ng / mL, about 1.6 ng / mL, about 1.65 ng / mL, about 1.7 ng / mL, about 1.75 ng / mL, about 1.8 ng / mL, about 1.85 ng / mL, about 1.9 ng / mL, about 1.95 ng / mL, about 2 ng / mL, about 2.05 ng / mL, about 2.1 ng / mL, about 2.15 ng / mL, about 2.2 ng / mL, about 2.25 ng / mL, about 2.3 ng / mL, about 2.35 ng / mL, about 2.4ng / mL, about 2.45ng / mL, about 2.5ng / mL, about 2.55ng / mL, about 2.6ng / mL, about 2.65ng / mL, about 2.7ng / mL, about 2.75ng / mL, about 2.8ng / mL, about 2.85ng / mL, about 2.9ng / mL, about 2.95ng / mL, about 3ng / mL, about 3.1ng / mL, about 3.2ng / mL, about 3.3ng / mL, about 3.4ng / mL, about 3.5ng / mL, about 3.6ng / mL, about 3.7ng / mL, about 3.8ng / mL, about 3.9ng / mL, about 4ng / mL, about 4.1ng / mL, about 4.2ng / mL, about 4.3ng / mL, about 4.4ng / mL, about 4.5ng / mL, about 4.6ng / mL, about 4.7ng / mL, about 4.8ng / mL, about 4.9ng / mL, about 5ng / mL, about 5.5ng / mL, about 6ng / mL, about 6.5ng / mL, about 7ng / mL, about 7.5ng / mL, about 8ng / mL, about 8.5ng / mL, about 9ng / mL, about 9.5 ng / mL, about 10 ng / mL, about 11 ng / mL, about 12 ng / mL, about 13 ng / mL, about 14 ng / mL, about 15 ng / mL, about 16 ng / mL, about 17 ng / mL, about 18 ng / mL, about 19 ng / mL, about 20 ng / mL, about 25 ng / mL, about 30 ng / mL, about 35 ng / mL, about 40 ng / mL, about 45 ng / mL, about 50 ng / mL, about 60 ng / mL, about 70 ng / mL, about 80 ng / mL, about 90 ng / mL, or about 100 ng / mL, or any range therebetween. .

[0118] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C maxFor each mg of β-lactam compound administered daily, about 0.5 ng / mL, about 0.55 ng / mL, about 0.6 ng / mL, about 0.65 ng / mL, about 0.7 ng / mL, about 0.75 ng / mL, about 0.8 ng / mL, about 0.85 ng / mL, about 0.9 ng / mL, about 0.95 ng / mL, about 1 ng / mL, about 1.05 ng / mL, about 1.1 ng / mL, about 1.15 ng / mL, about 1.2 ng / mL, about 1.25 ng / mL, about 1.3 ng / mL, about 1.35 ng / mL, about 1.4 ng / mL, about 1.45 ng / mL, about 1.5 ng / mL, about 1.55 ng / mL, about 1.6 ng / mL, about 1.65 ng / mL, about 1.7 ng / mL, about 1.75 ng / mL, about 1.8 ng / mL, about 1.85 ng / mL, about 1.9 ng / mL, about 1.95 ng / mL, about 2 ng / mL, about 2.05 ng / mL, about 2.1 ng / mL, about 2.15 ng / mL, about 2.2 ng / mL, about 2.25 ng / mL, about 2.3 ng / mL, about 2.35 ng / mL, about 2.4ng / mL, about 2.45ng / mL, about 2.5ng / mL, about 2.55ng / mL, about 2.6ng / mL, about 2.65ng / mL, about 2.7ng / mL, about 2.75ng / mL, about 2.8ng / mL, about 2.85ng / mL, about 2.9ng / mL, about 2.95ng / mL, about 3ng / mL, about 3.1ng / mL, about 3.2ng / mL, about 3.3ng / mL, about 3.4ng / mL, about 3.5ng / mL, about 3.6ng / mL, about 3.7ng / mL, about 3.8ng / mL, about 3.9ng / mL, about 4ng / mL, about 4.1ng / mL, about 4.2ng / mL, about 4.3ng / mL, about 4.4ng / mL, about 4.5ng / mL, about 4.6ng / mL, about 4.7ng / mL, about 4.8ng / mL, about 4.9ng / mL, about 5ng / mL, about 5.5ng / mL, about 6ng / mL, about 6.5ng / mL, about 7ng / mL, about 7.5ng / mL, about 8ng / mL, about 8.5ng / mL, about 9ng / mL, about 9.5 ng / mL, about 10 ng / mL, about 11 ng / mL, about 12 ng / mL, about 13 ng / mL, about 14 ng / mL, about 15 ng / mL, about 16 ng / mL, about 17 ng / mL, about 18 ng / mL, about 19 ng / mL, about 20 ng / mL, about 25 ng / mL, about 30 ng / mL, about 35 ng / mL, about 40 ng / mL, about 45 ng / mL, about 50 ng / mL, about 60 ng / mL, about 70 ng / mL, about 80 ng / mL, about 90 ng / mL, or about 100 ng / mL, or any range therebetween. .

[0119] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C maxFor each mg of β-lactam compound administered daily, about 0.5 ng / mL, about 0.55 ng / mL, about 0.6 ng / mL, about 0.65 ng / mL, about 0.7 ng / mL, about 0.75 ng / mL, about 0.8 ng / mL, about 0.85 ng / mL, about 0.9 ng / mL, about 0.95 ng / mL, about 1 ng / mL, about 1.05 ng / mL, about 1.1 ng / mL, about 1.15 ng / mL, about 1.2 ng / mL, about 1.25 ng / mL, about 1.3 ng / mL, about 1.35 ng / mL, about 1.4 ng / mL, about 1.45 ng / mL, about 1.5 ng / mL, about 1.55 ng / mL, about 1.6 ng / mL, about 1.65 ng / mL, about 1.7 ng / mL, about 1.75 ng / mL, about 1.8 ng / mL, about 1.85 ng / mL, about 1.9 ng / mL, about 1.95 ng / mL, about 2 ng / mL, about 2.05 ng / mL, about 2.1 ng / mL, about 2.15 ng / mL, about 2.2 ng / mL, about 2.25 ng / mL, about 2.3 ng / mL, about 2.35 ng / mL, about 2.4ng / mL, about 2.45ng / mL, about 2.5ng / mL, about 2.55ng / mL, about 2.6ng / mL, about 2.65ng / mL, about 2.7ng / mL, about 2.75ng / mL, about 2.8ng / mL, about 2.85ng / mL, about 2.9ng / mL, about 2.95ng / mL, about 3ng / mL, about 3.1ng / mL, about 3.2ng / mL, about 3.3ng / mL, about 3.4ng / mL, about 3.5ng / mL, about 3.6ng / mL, about 3.7ng / mL, about 3.8ng / mL, about 3.9ng / mL, about 4ng / mL, about 4.1ng / mL, about 4.2ng / mL, about 4.3ng / mL, about 4.4ng / mL, about 4.5ng / mL, about 4.6ng / mL, about 4.7ng / mL, about 4.8ng / mL, about 4.9ng / mL, about 5ng / mL, about 5.5ng / mL, about 6ng / mL, about 6.5ng / mL, about 7ng / mL, about 7.5ng / mL, about 8ng / mL, about 8.5ng / mL, about 9ng / mL, about 9.5 ng / mL, about 10 ng / mL, about 11 ng / mL, about 12 ng / mL, about 13 ng / mL, about 14 ng / mL, about 15 ng / mL, about 16 ng / mL, about 17 ng / mL, about 18 ng / mL, about 19 ng / mL, about 20 ng / mL, about 25 ng / mL, about 30 ng / mL, about 35 ng / mL, about 40 ng / mL, about 45 ng / mL, about 50 ng / mL, about 60 ng / mL, about 70 ng / mL, about 80 ng / mL, about 90 ng / mL, or about 100 ng / mL, or any range therebetween. .

[0120] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C maxFor each mg of β-lactam compound administered daily, about 0.5 ng / mL, about 0.55 ng / mL, about 0.6 ng / mL, about 0.65 ng / mL, about 0.7 ng / mL, about 0.75 ng / mL, about 0.8 ng / mL, about 0.85 ng / mL, about 0.9 ng / mL, about 0.95 ng / mL, about 1 ng / mL, about 1.05 ng / mL, about 1.1 ng / mL, about 1.15 ng / mL, about 1.2 ng / mL, about 1.25 ng / mL, about 1.3 ng / mL, about 1.35 ng / mL, about 1.4 ng / mL, about 1.45 ng / mL, about 1.5 ng / mL, about 1.55 ng / mL, about 1.6 ng / mL, about 1.65 ng / mL, about 1.7 ng / mL, about 1.75 ng / mL, about 1.8 ng / mL, about 1.85 ng / mL, about 1.9 ng / mL, about 1.95 ng / mL, about 2 ng / mL, about 2.05 ng / mL, about 2.1 ng / mL, about 2.15 ng / mL, about 2.2 ng / mL, about 2.25 ng / mL, about 2.3 ng / mL, about 2.35 ng / mL, about 2.4ng / mL, about 2.45ng / mL, about 2.5ng / mL, about 2.55ng / mL, about 2.6ng / mL, about 2.65ng / mL, about 2.7ng / mL, about 2.75ng / mL, about 2.8ng / mL, about 2.85ng / mL, about 2.9ng / mL, about 2.95ng / mL, about 3ng / mL, about 3.1ng / mL, about 3.2ng / mL, about 3.3ng / mL, about 3.4ng / mL, about 3.5ng / mL, about 3.6ng / mL, about 3.7ng / mL, about 3.8ng / mL, about 3.9ng / mL, about 4ng / mL, about 4.1ng / mL, about 4.2ng / mL, about 4.3ng / mL, about 4.4ng / mL, about 4.5ng / mL, about 4.6ng / mL, about 4.7ng / mL, about 4.8ng / mL, about 4.9ng / mL, about 5ng / mL, about 5.5ng / mL, about 6ng / mL, about 6.5ng / mL, about 7ng / mL, about 7.5ng / mL, about 8ng / mL, about 8.5ng / mL, about 9ng / mL, about 9.5 ng / mL, about 10 ng / mL, about 11 ng / mL, about 12 ng / mL, about 13 ng / mL, about 14 ng / mL, about 15 ng / mL, about 16 ng / mL, about 17 ng / mL, about 18 ng / mL, about 19 ng / mL, about 20 ng / mL, about 25 ng / mL, about 30 ng / mL, about 35 ng / mL, about 40 ng / mL, about 45 ng / mL, about 50 ng / mL, about 60 ng / mL, about 70 ng / mL, about 80 ng / mL, about 90 ng / mL, or about 100 ng / mL, or any range therebetween. .

[0121] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on the first day of administration is about 0.5 hr*ng / mL, about 0.55 hr*ng / mL, about 0.6 hr*ng / mL, about 0.65 hr*ng / mL, about 0.7 hr*ng / mL, about 0.75 hr*ng / mL, about 0.8 hr*ng / mL, about 0.85 hr*ng / mL, about 0.9 hr*ng / mL, about 0.95 hr*ng / mL, about 1 hr*ng / mL, about 1.05 hr*ng / mL, about 1.1 hr*ng / mL, about 1.15 hr*ng / mL, about 1.25 hr*ng / mL, about 1.35 hr*ng / mL, about 1.40 hr*ng / mL, about 1.65 hr*ng / mL, about 1.75 hr*ng / mL, about 1.80 hr*ng / mL, about 1.90 hr*ng / mL, about 2.05 hr*ng / mL, about 2.15 hr*ng / mL, about 2.20 hr*ng / mL, about 2.30 hr*ng / mL, about 2.40 hr*ng / mL, about 2.50 hr*ng / mL hr*ng / mL, about 1.2hr*ng / mL, about 1.25hr*ng / mL, about 1.3hr*ng / mL, about 1.35hr*ng / mL, about 1.4hr*ng / mL, about 1.45hr*ng / mL, about 1.5hr*ng / mL, about 1.55hr*ng / mL, about 1.6hr*ng / mL, about 1.65hr*ng / mL, about 1.7hr*ng / mL, about 1.75hr*ng / mL, about 1.8hr*ng / mL, about 1.85hr*ng / mL, about 1.9hr*ng / mL, about 1.95hr*ng / mL, about 2hr*ng / mL, about 2.05hr*ng / mL, about 2.1 hr*ng / mL, about 2.15 hr*ng / mL, about 2.2 hr*ng / mL, about 2.25 hr*ng / mL, about 2.3 hr*ng / mL, about 2.35 hr*ng / mL, about 2.4 hr*ng / mL, about 2.45 hr*ng / mL, about 2.5 hr*ng / mL, about 2.55 hr*ng / mL, about 2.6 hr*ng / mL, about 2.65 hr*ng / mL, about 2.7 hr*ng / mL, about 2.75 hr*ng / mL, about 2.8 hr*ng / mL, about 2.85 hr*ng / mL, about 2.9 hr*ng / mL, about 2.95 hr*ng / mL , about 3hr*ng / mL, about 3.1hr*ng / mL, about 3.2hr*ng / mL, about 3.3hr*ng / mL, about 3.4hr*ng / mL, about 3.5hr*ng / mL, about 3.6hr*ng / mL, about 3.7hr*ng / mL, about 3.8hr*ng / mL, about 3.9hr*ng / mL, about 4hr*ng / mL, about 4.1hr*ng / mL, about 4.2hr*ng / mL, about 4.3hr*ng / mL, about 4.4hr*ng / mL, about 4.5hr*ng / mL, about 4.6hr*ng / mL, about 4.7hr*ng / mL, about 4.8hr*ng / mL, about 4.9hr*ng / mL, about 5.1hr*ng / mL, about 5.2hr*ng / mL, about 5.3hr*ng / mL, about 5.4hr*ng / mL, about 5.5hr*ng / mL, about 5.6hr*ng / mL, about 5.7hr*ng / mL, about 5.8hr*ng / mL, about 5.9hr*ng / mL, about 6.9hr*ng / mL, about 5hr*ng / mL, about 5.5hr*ng / mL, about 6hr*ng / mL, about 6.5hr*ng / mL, about 7hr*ng / mL, about 7.5hr*ng / mL, about 8hr*ng / mL, about 8.5hr*ng / mL, about 9hr*ng / mL, about 9.5hr*ng / mL, about 10hr*ng / mL, about 11hr*ng / mL, about 12hr*ng / mL, about 13hr*ng / mL, about 14hr*ng / mL, about 15hr*ng / mL, about 16 hr*ng / mL, about 17 hr*ng / mL, about 18 hr*ng / mL, about 19 hr*ng / mL, about 20 hr*ng / mL, about 25 hr*ng / mL, about 30 hr*ng / mL, about 35 hr*ng / mL, about 40 hr*ng / mL, about 45 hr*ng / mL, about 50 hr*ng / mL, about 60 hr*ng / mL, about 70 hr*ng / mL, about 80 hr*ng / mL, about 90 hr*ng / mL, or about 100 hr*ng / mL, or any range therebetween. .

[0122] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on the 7th day of the administration is about 0.5 hr*ng / mL, about 0.55 hr*ng / mL, about 0.6 hr*ng / mL, about 0.65 hr*ng / mL, about 0.7 hr*ng / mL, about 0.75 hr*ng / mL, about 0.8 hr*ng / mL, about 0.85 hr*ng / mL, about 0.9 hr*ng / mL, about 0.95 hr*ng / mL, about 1 hr*ng / mL, about 1.05 hr*ng / mL, about 1.1 hr*ng / mL, about 1.15 hr*ng / mL, about 1.25 hr*ng / mL, about 1.35 hr*ng / mL, about 1.40 hr*ng / mL, about 1.65 hr*ng / mL, about 1.75 hr*ng / mL, about 1.80 hr*ng / mL, about 1.90 hr*ng / mL, about 2.05 hr*ng / mL, about 2.15 hr*ng / mL, about 2.20 hr*ng / mL, about 2.30 hr*ng / mL, about 2.40 hr*ng / mL, about 2.50 hr*ng / mL hr*ng / mL, about 1.2hr*ng / mL, about 1.25hr*ng / mL, about 1.3hr*ng / mL, about 1.35hr*ng / mL, about 1.4hr*ng / mL, about 1.45hr*ng / mL, about 1.5hr*ng / mL, about 1.55hr*ng / mL, about 1.6hr*ng / mL, about 1.65hr*ng / mL, about 1.7hr*ng / mL, about 1.75hr*ng / mL, about 1.8hr*ng / mL, about 1.85hr*ng / mL, about 1.9hr*ng / mL, about 1.95hr*ng / mL, about 2hr*ng / mL, about 2.05hr*ng / mL, about 2.1 hr*ng / mL, about 2.15 hr*ng / mL, about 2.2 hr*ng / mL, about 2.25 hr*ng / mL, about 2.3 hr*ng / mL, about 2.35 hr*ng / mL, about 2.4 hr*ng / mL, about 2.45 hr*ng / mL, about 2.5 hr*ng / mL, about 2.55 hr*ng / mL, about 2.6 hr*ng / mL, about 2.65 hr*ng / mL, about 2.7 hr*ng / mL, about 2.75 hr*ng / mL, about 2.8 hr*ng / mL, about 2.85 hr*ng / mL, about 2.9 hr*ng / mL, about 2.95 hr*ng / mL , about 3hr*ng / mL, about 3.1hr*ng / mL, about 3.2hr*ng / mL, about 3.3hr*ng / mL, about 3.4hr*ng / mL, about 3.5hr*ng / mL, about 3.6hr*ng / mL, about 3.7hr*ng / mL, about 3.8hr*ng / mL, about 3.9hr*ng / mL, about 4hr*ng / mL, about 4.1hr*ng / mL, about 4.2hr*ng / mL, about 4.3hr*ng / mL, about 4.4hr*ng / mL, about 4.5hr*ng / mL, about 4.6hr*ng / mL, about 4.7hr*ng / mL, about 4.8hr*ng / mL, about 4.9hr*ng / mL, about 5.1hr*ng / mL, about 5.2hr*ng / mL, about 5.3hr*ng / mL, about 5.4hr*ng / mL, about 5.5hr*ng / mL, about 5.6hr*ng / mL, about 5.7hr*ng / mL, about 5.8hr*ng / mL, about 5.9hr*ng / mL, about 6.9hr*ng / mL, about 5hr*ng / mL, about 5.5hr*ng / mL, about 6hr*ng / mL, about 6.5hr*ng / mL, about 7hr*ng / mL, about 7.5hr*ng / mL, about 8hr*ng / mL, about 8.5hr*ng / mL, about 9hr*ng / mL, about 9.5hr*ng / mL, about 10hr*ng / mL, about 11hr*ng / mL, about 12hr*ng / mL, about 13hr*ng / mL, about 14hr*ng / mL, about 15hr*ng / mL, about 16 hr*ng / mL, about 17 hr*ng / mL, about 18 hr*ng / mL, about 19 hr*ng / mL, about 20 hr*ng / mL, about 25 hr*ng / mL, about 30 hr*ng / mL, about 35 hr*ng / mL, about 40 hr*ng / mL, about 45 hr*ng / mL, about 50 hr*ng / mL, about 60 hr*ng / mL, about 70 hr*ng / mL, about 80 hr*ng / mL, about 90 hr*ng / mL, or about 100 hr*ng / mL, or any range therebetween. .

[0123] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the subject in need thereof on the first day of the administration is about 0.5 hr*ng / mL, about 0.55 hr*ng / mL, about 0.6 hr*ng / mL, about 0.65 hr*ng / mL, about 0.7 hr*ng / mL, about 0.75 hr*ng / mL, about 0.8 hr*ng / mL, about 0.85 hr*ng / mL, about 0.9 hr*ng / mL, about 0.95 hr*ng / mL, about 1 hr*ng / mL, about 1.05 hr*ng / mL, about 1.1 hr*ng / mL, about 1.2 hr*ng / mL, about 1.3 hr*ng / mL, about 1.4 hr*ng / mL, about 1.6 hr*ng / mL, about 1.8 hr*ng / mL, about 1.9 hr*ng / mL, about 2.3 hr*ng / mL, about 2.4 hr*ng / mL, about 2.5 hr*ng / mL, about 2.6 hr*ng / mL, about 2.7 hr*ng / mL, about 2.8 15hr*ng / mL, about 1.2hr*ng / mL, about 1.25hr*ng / mL, about 1.3hr*ng / mL, about 1.35hr*ng / mL, about 1.4hr*ng / mL, about 1.45hr*ng / mL, about 1.5hr*ng / mL, about 1.55hr*ng / mL, about 1.6hr*ng / mL, about 1.65hr*ng / mL, about 1.7hr*ng / mL, about 1.75hr*ng / mL, about 1.8hr*ng / mL, about 1.85hr*ng / mL, about 1.9hr*ng / mL, about 1.95hr*ng / mL, about 2hr*ng / mL, about 2.05hr*ng / mL g / mL, about 2.1 hr*ng / mL, about 2.15 hr*ng / mL, about 2.2 hr*ng / mL, about 2.25 hr*ng / mL, about 2.3 hr*ng / mL, about 2.35 hr*ng / mL, about 2.4 hr*ng / mL, about 2.45 hr*ng / mL, about 2.5 hr*ng / mL, about 2.55 hr*ng / mL, about 2.6 hr*ng / mL, about 2.65 hr*ng / mL, about 2.7 hr*ng / mL, about 2.75 hr*ng / mL, about 2.8 hr*ng / mL, about 2.85 hr*ng / mL, about 2.9 hr*ng / mL, about 2.95 hr*ng / mL , about 3hr*ng / mL, about 3.1hr*ng / mL, about 3.2hr*ng / mL, about 3.3hr*ng / mL, about 3.4hr*ng / mL, about 3.5hr*ng / mL, about 3.6hr*ng / mL, about 3.7hr*ng / mL, about 3.8hr*ng / mL, about 3.9hr*ng / mL, about 4hr*ng / mL, about 4.1hr*ng / mL, about 4.2hr*ng / mL, about 4.3hr*ng / mL, about 4.4hr*ng / mL, about 4.5hr*ng / mL, about 4.6hr*ng / mL, about 4.7hr*ng / mL, about 4.8hr*ng / mL, about 4.9hr*ng / mL, about 5.1hr*ng / mL, about 5.2hr*ng / mL, about 5.3hr*ng / mL, about 5.4hr*ng / mL, about 5.5hr*ng / mL, about 5.6hr*ng / mL, about 5.7hr*ng / mL, about 5.8hr*ng / mL, about 5.9hr*ng / mL, about 6.9hr*ng / mL, about 5hr*ng / mL, about 5.5hr*ng / mL, about 6hr*ng / mL, about 6.5hr*ng / mL, about 7hr*ng / mL, about 7.5hr*ng / mL, about 8hr*ng / mL, about 8.5hr*ng / mL, about 9hr*ng / mL, about 9.5hr*ng / mL, about 10hr*ng / mL, about 11hr*ng / mL, about 12hr*ng / mL, about 13hr*ng / mL, about 14hr*ng / mL, about 15hr*ng / mL, about 16 hr*ng / mL, about 17 hr*ng / mL, about 18 hr*ng / mL, about 19 hr*ng / mL, about 20 hr*ng / mL, about 25 hr*ng / mL, about 30 hr*ng / mL, about 35 hr*ng / mL, about 40 hr*ng / mL, about 45 hr*ng / mL, about 50 hr*ng / mL, about 60 hr*ng / mL, about 70 hr*ng / mL, about 80 hr*ng / mL, about 90 hr*ng / mL, or about 100 hr*ng / mL, or any range therebetween. .

[0124] In some embodiments, on the 7th day of said administration in the subject in need thereof, the AUC of the plasma concentration of the β-lactam compound obtained is about 0.5 hr*ng / mL, about 0.55 hr*ng / mL, about 0.6 hr*ng / mL, about 0.65 hr*ng / mL, about 0.7 hr*ng / mL, about 0.75 hr*ng / mL, about 0.8 hr*ng / mL, about 0.85 hr*ng / mL, about 0.9 hr*ng / mL, about 0.95 hr*ng / mL, about 1 hr*ng / mL, about 1.05 hr*ng / mL, about 1.1 hr*ng / mL, about 1.2 hr*ng / mL, about 1.3 hr*ng / mL, about 1.4 hr*ng / mL, about 1.6 hr*ng / mL, about 1.8 hr*ng / mL, about 1.9 hr*ng / mL, about 2.3 hr*ng / mL, about 2.4 hr*ng / mL, about 2.5 hr*ng / mL, about 2.6 hr*ng / mL, about 2.7 hr*ng / mL, about 2.8 15hr*ng / mL, about 1.2hr*ng / mL, about 1.25hr*ng / mL, about 1.3hr*ng / mL, about 1.35hr*ng / mL, about 1.4hr*ng / mL, about 1.45hr*ng / mL, about 1.5hr*ng / mL, about 1.55hr*ng / mL, about 1.6hr*ng / mL, about 1.65hr*ng / mL, about 1.7hr*ng / mL, about 1.75hr*ng / mL, about 1.8hr*ng / mL, about 1.85hr*ng / mL, about 1.9hr*ng / mL, about 1.95hr*ng / mL, about 2hr*ng / mL, about 2.05hr*ng / mL g / mL, about 2.1 hr*ng / mL, about 2.15 hr*ng / mL, about 2.2 hr*ng / mL, about 2.25 hr*ng / mL, about 2.3 hr*ng / mL, about 2.35 hr*ng / mL, about 2.4 hr*ng / mL, about 2.45 hr*ng / mL, about 2.5 hr*ng / mL, about 2.55 hr*ng / mL, about 2.6 hr*ng / mL, about 2.65 hr*ng / mL, about 2.7 hr*ng / mL, about 2.75 hr*ng / mL, about 2.8 hr*ng / mL, about 2.85 hr*ng / mL, about 2.9 hr*ng / mL, about 2.95 hr*ng / mL , about 3hr*ng / mL, about 3.1hr*ng / mL, about 3.2hr*ng / mL, about 3.3hr*ng / mL, about 3.4hr*ng / mL, about 3.5hr*ng / mL, about 3.6hr*ng / mL, about 3.7hr*ng / mL, about 3.8hr*ng / mL, about 3.9hr*ng / mL, about 4hr*ng / mL, about 4.1hr*ng / mL, about 4.2hr*ng / mL, about 4.3hr*ng / mL, about 4.4hr*ng / mL, about 4.5hr*ng / mL, about 4.6hr*ng / mL, about 4.7hr*ng / mL, about 4.8hr*ng / mL, about 4.9hr*ng / mL, about 5.1hr*ng / mL, about 5.2hr*ng / mL, about 5.3hr*ng / mL, about 5.4hr*ng / mL, about 5.5hr*ng / mL, about 5.6hr*ng / mL, about 5.7hr*ng / mL, about 5.8hr*ng / mL, about 5.9hr*ng / mL, about 6.9hr*ng / mL, about 5hr*ng / mL, about 5.5hr*ng / mL, about 6hr*ng / mL, about 6.5hr*ng / mL, about 7hr*ng / mL, about 7.5hr*ng / mL, about 8hr*ng / mL, about 8.5hr*ng / mL, about 9hr*ng / mL, about 9.5hr*ng / mL, about 10hr*ng / mL, about 11hr*ng / mL, about 12hr*ng / mL, about 13hr*ng / mL, about 14hr*ng / mL, about 15hr*ng / mL, about 16 hr*ng / mL, about 17 hr*ng / mL, about 18 hr*ng / mL, about 19 hr*ng / mL, about 20 hr*ng / mL, about 25 hr*ng / mL, about 30 hr*ng / mL, about 35 hr*ng / mL, about 40 hr*ng / mL, about 45 hr*ng / mL, about 50 hr*ng / mL, about 60 hr*ng / mL, about 70 hr*ng / mL, about 80 hr*ng / mL, about 90 hr*ng / mL, or about 100 hr*ng / mL, or any range therebetween. .

[0125] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max In the range of about 1500 ng / mL to about 2500 ng / mL, about 1600 ng / mL to about 2400 ng / mL, about 1700 ng / mL to about 2300 ng / mL, about 1800 ng / mL to about 2200 ng / mL, about 1900 ng / mL to about 2100 ng / mL, about 1950 ng / mL to about 2050 ng / mL, about 1980 ng / mL to about 2020 ng / mL, about 1990 ng / mL to about 2010 ng / mL.

[0126] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max It is about 2000ng / mL.

[0127] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C maxIn the range of about 700 ng / mL to about 1800 ng / mL, about 800 ng / mL to about 1700 ng / mL, about 900 ng / mL to about 1600 ng / mL, about 1000 ng / mL to about 1500 ng / mL, about 1100 ng / mL to about 1400 ng / mL, about 1200 ng / mL to about 1300 ng / mL, about 1230 ng / mL to about 1270 ng / mL, about 1240 ng / mL to about 1260 ng / mL.

[0128] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C max It is about 1250ng / mL.

[0129] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max In the range of about 1600 ng / mL to about 2700 ng / mL, about 1700 ng / mL to about 2600 ng / mL, about 1800 ng / mL to about 2500 ng / mL, about 1900 ng / mL to about 2400 ng / mL, about 2000 ng / mL to about 2300 ng / mL, about 2100 ng / mL to about 2200 ng / mL, about 2130 ng / mL to about 2170 ng / mL, about 2140 ng / mL to about 2160 ng / mL.

[0130] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max It is about 2150ng / mL.

[0131] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max In the range of about 1600 ng / mL to about 2700 ng / mL, about 1700 ng / mL to about 2600 ng / mL, about 1800 ng / mL to about 2500 ng / mL, about 1900 ng / mL to about 2400 ng / mL, about 2000 ng / mL to about 2300 ng / mL, about 2050 ng / mL to about 2200 ng / mL, about 2100 ng / mL to about 2140 ng / mL, about 2110 ng / mL to about 2130 ng / mL.

[0132] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is Cmax It is about 2120ng / mL.

[0133] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max In the range of about 1200 ng / mL to about 2200 ng / mL, about 1300 ng / mL to about 2100 ng / mL, about 1400 ng / mL to about 2000 ng / mL, about 1500 ng / mL to about 1900 ng / mL, about 1600 ng / mL to about 1800 ng / mL, about 1650 ng / mL to about 1750 ng / mL, about 1680 ng / mL to about 1720 ng / mL, about 1690 ng / mL to about 1710 ng / mL.

[0134] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C max It is about 1700ng / mL.

[0135] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C max In the range of about 800 ng / mL to about 1800 ng / mL, about 900 ng / mL to about 1700 ng / mL, about 1000 ng / mL to about 1600 ng / mL, about 1100 ng / mL to about 1500 ng / mL, about 1200 ng / mL to about 1400 ng / mL, about 1250 ng / mL to about 1350 ng / mL, about 1270 ng / mL to about 1310 ng / mL, about 1280 ng / mL to about 1300 ng / mL.

[0136] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C max It is about 1290ng / mL.

[0137] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C maxIn the range of about 1200 ng / mL to about 2200 ng / mL, about 1300 ng / mL to about 2100 ng / mL, about 1400 ng / mL to about 2000 ng / mL, about 1500 ng / mL to about 1900 ng / mL, about 1600 ng / mL to about 1850 ng / mL, about 1650 ng / mL to about 1800 ng / mL, about 1700 ng / mL to about 1740 ng / mL, about 1710 ng / mL to about 1730 ng / mL.

[0138] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C max It is about 1720ng / mL.

[0139] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max In the range of about 900 ng / mL to about 2000 ng / mL, about 1000 ng / mL to about 1900 ng / mL, about 1100 ng / mL to about 1800 ng / mL, about 1200 ng / mL to about 1700 ng / mL, about 1300 ng / mL to about 1600 ng / mL, about 1400 ng / mL to about 1550 ng / mL, about 1460 ng / mL to about 1500 ng / mL, about 1470 ng / mL to about 1490 ng / mL.

[0140] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C max It is about 1480ng / mL.

[0141] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the comparable subjects on the first day of said dosing is in the range of about 2500 hr*ng / mL to about 3200 hr*ng / mL, about 2600 hr*ng / mL to about 3100 hr*ng / mL, about 2700 hr*ng / mL to about 3000 hr*ng / mL, about 2750 hr*ng / mL to about 2950 hr*ng / mL, about 2800 hr*ng / mL to about 2870 hr*ng / mL, in the range of about 2810 hr*ng / mL to about 2860 hr*ng / mL, or about 2820 hr*ng / mL to about 2850 hr*ng / mL.

[0142] In some embodiments, the resulting plasma concentration of the β-lactam compound in the comparable subject on the first day of the administration has an AUC of about 2840 hr*ng / mL.

[0143] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the comparable subjects on day 7 of the dosing is in the range of about 1600 hr*ng / mL to about 2200 hr*ng / mL, about 1700 hr*ng / mL to about 2100 hr*ng / mL, about 1800 hr*ng / mL to about 2000 hr*ng / mL, about 1850 hr*ng / mL to about 1950 hr*ng / mL, about 1860 hr*ng / mL to about 1920 hr*ng / mL, in the range of about 1870 hr*ng / mL to about 1910 hr*ng / mL, or about 1880 hr*ng / mL to about 1900 hr*ng / mL.

[0144] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the dosing is about 1890 hr*ng / mL.

[0145] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of said dosing has an AUC ranging from about 3900 hr*ng / mL to about 4500 hr*ng / mL, from about 4000 hr*ng / mL to about 4400 hr*ng / mL, from about 4100 hr*ng / mL to about 4300 hr*ng / mL, from about 4150 hr*ng / mL to about 4250 hr*ng / mL, from about 4160 hr*ng / mL to about 4220 hr*ng / mL, from about 4170 hr*ng / mL to about 4210 hr*ng / mL, or from about 4180 hr*ng / mL to about 4200 hr*ng / mL.

[0146] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of said dosing has an AUC of about 4190 hr*ng / mL.

[0147] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing has an AUC in the range of about 4100 hr*ng / mL to about 4700 hr*ng / mL, about 4200 hr*ng / mL to about 4600 hr*ng / mL, about 4300 hr*ng / mL to about 4500 hr*ng / mL, about 4350 hr*ng / mL to about 4450 hr*ng / mL, about 4370 hr*ng / mL to about 4430 hr*ng / mL, in the range of about 4380 hr*ng / mL to about 4420 hr*ng / mL, or about 4390 hr*ng / mL to about 4410 hr*ng / mL.

[0148] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing has an AUC of about 4400 hr*ng / mL.

[0149] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the comparable subjects on the first day of said dosing is in the range of about 3200 hr*ng / mL to about 4000 hr*ng / mL, about 3300 hr*ng / mL to about 3900 hr*ng / mL, about 3400 hr*ng / mL to about 3800 hr*ng / mL, about 3500 hr*ng / mL to about 3700 hr*ng / mL, about 3590 hr*ng / mL to about 3650 hr*ng / mL, in the range of about 3600 hr*ng / mL to about 3640 hr*ng / mL, or about 3610 hr*ng / mL to about 3630 hr*ng / mL.

[0150] In some embodiments, the resulting plasma concentration of the β-lactam compound in the comparable subject on the first day of the administration has an AUC of about 3620 hr*ng / mL.

[0151] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the comparable subjects on day 7 of the dosing is in the range of about 2200 hr*ng / mL to about 3100 hr*ng / mL, about 2300 hr*ng / mL to about 3000 hr*ng / mL, about 2400 hr*ng / mL to about 2900 hr*ng / mL, about 2500 hr*ng / mL to about 2800 hr*ng / mL, about 2600 hr*ng / mL to about 2700 hr*ng / mL, in the range of about 2610 hr*ng / mL to about 2650 hr*ng / mL, or about 2620 hr*ng / mL to about 2640 hr*ng / mL.

[0152] In some embodiments, the resulting plasma concentration of the β-lactam compound in the comparable subject on day 7 of the dosing has an AUC of about 2630 hr*ng / mL.

[0153] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of said dosing has an AUC ranging from about 3400 hr*ng / mL to about 4300 hr*ng / mL, from about 3500 hr*ng / mL to about 4200 hr*ng / mL, from about 3600 hr*ng / mL to about 4100 hr*ng / mL, from about 3700 hr*ng / mL to about 4000 hr*ng / mL, from about 3800 hr*ng / mL to about 3900 hr*ng / mL, from about 3840 hr*ng / mL to about 3880 hr*ng / mL, or from about 3850 hr*ng / mL to about 3870 hr*ng / mL.

[0154] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of said dosing has an AUC of about 3860 hr*ng / mL.

[0155] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing has an AUC ranging from about 3900 hr*ng / mL to about 4700 hr*ng / mL, about 4000 hr*ng / mL to about 4600 hr*ng / mL, about 4100 hr*ng / mL to about 4400 hr*ng / mL, about 4200 hr*ng / mL to about 4400 hr*ng / mL, about 4250 hr*ng / mL to about 4350 hr*ng / mL, about 4260 hr*ng / mL to about 4300 hr*ng / mL, or about 4270 hr*ng / mL to about 4290 hr*ng / mL.

[0156] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing has an AUC of about 4280 hr*ng / mL.

[0157] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subject on the first day of the administration is C maxabout 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, about 750 ng / mL, about 800 ng / mL, about 850 ng / mL, about 900 ng / mL, about 950 ng / mL, about 1000 ng / mL, about 1050 ng / mL, about 1100 ng / mL, about 1150 ng / mL, about 1200 ng / mL, about 1250 ng / mL, about 1300ng / mL, about 1350ng / mL, about 1400ng / mL, about 1450ng / mL, about 1500ng / mL, about 1550ng / mL, about 1600ng / mL, about 1650ng / mL, about 1700ng / mL, about 1750ng / mL, about 1800ng / mL, about 1850ng / mL, about 1900ng / mL, about 1950ng / mL, about 2000ng / mL, about 2050ng / mL, about 2100ng / mL, about 2150ng / mL, about 2200ng / mL, about 2250ng / mL, about 2300ng / mL, about 2350ng / mL, about 2400ng / mL mL, about 2450 ng / mL, about 2500 ng / mL, about 2550 ng / mL, about 2600 ng / mL, about 2650 ng / mL, about 2700 ng / mL, about 2750 ng / mL, about 2800 ng / mL, about 2850 ng / mL, about 2900 ng / mL, about 2950 ng / mL, about 3000 ng / mL, about 3050 ng / mL, about 3100 ng / mL, about 3150 ng / mL, about 3200 ng / mL, about 3250 ng / mL, about 3300 ng / mL, about 3350 ng / mL, about 3400 ng / mL, about 3450 ng / mL, about 3500 ng / mL, about 355 0 ng / mL, about 3600 ng / mL, about 3650 ng / mL, about 3700 ng / mL, about 3750 ng / mL, about 3800 ng / mL, about 3850 ng / mL, about 3900 ng / mL, about 3950 ng / mL, about 4000 ng / mL, about 4050 ng / mL, about 4100 ng / mL, about 4150 ng / mL, about 4200 ng / mL, about 4250 ng / mL, about 4300 ng / mL, about 4350 ng / mL, about 4400 ng / mL, about 4450 ng / mL, about 4500 ng / mL, about 4550 ng / mL, about 4600 ng / mL, about 4650 ng / mL,about 4700 ng / mL, about 4750 ng / mL, about 4800 ng / mL, about 4850 ng / mL, about 4900 ng / mL, about 4950 ng / mL, about 5000 ng / mL, about 5100 ng / mL, about 5200 ng / mL, about 5300 ng / mL, about 5400 ng / mL, about 5500 ng / mL, about 5600 ng / mL, about 5700 ng / mL, about 5800 ng / mL, about 5900 ng / mL, about 6000 ng / mL, about 6500 ng / mL, about 7000 ng / mL, about 7500 ng / mL, about 8000 ng / mL, about 8500 ng / mL, about 9000 ng / mL, about 9500 ng / mL, about 10000 ng / mL, about 11000 ng / mL, about 12000 ng / mL, about 13000 ng / mL, about 14000 ng / mL, about 15000 ng / mL, about 16000 ng / mL, about 17000 ng / mL, about 18000 ng / mL, about 19000 ng / mL, or about 20000 ng / mL, or any range therebetween.

[0158] In some embodiments, the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is C maxabout 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, about 750 ng / mL, about 800 ng / mL, about 850 ng / mL, about 900 ng / mL, about 950 ng / mL, about 1000 ng / mL, about 1050 ng / mL, about 1100 ng / mL, about 1150 ng / mL, about 1200 ng / mL, about 1250 ng / mL, about 1300ng / mL, about 1350ng / mL, about 1400ng / mL, about 1450ng / mL, about 1500ng / mL, about 1550ng / mL, about 1600ng / mL, about 1650ng / mL, about 1700ng / mL, about 1750ng / mL, about 1800ng / mL, about 1850ng / mL, about 1900ng / mL, about 1950ng / mL, about 2000ng / mL, about 2050ng / mL, about 2100ng / mL, about 2150ng / mL, about 2200ng / mL, about 2250ng / mL, about 2300ng / mL, about 2350ng / mL, about 2400ng / mL mL, about 2450 ng / mL, about 2500 ng / mL, about 2550 ng / mL, about 2600 ng / mL, about 2650 ng / mL, about 2700 ng / mL, about 2750 ng / mL, about 2800 ng / mL, about 2850 ng / mL, about 2900 ng / mL, about 2950 ng / mL, about 3000 ng / mL, about 3050 ng / mL, about 3100 ng / mL, about 3150 ng / mL, about 3200 ng / mL, about 3250 ng / mL, about 3300 ng / mL, about 3350 ng / mL, about 3400 ng / mL, about 3450 ng / mL, about 3500 ng / mL, about 355 0 ng / mL, about 3600 ng / mL, about 3650 ng / mL, about 3700 ng / mL, about 3750 ng / mL, about 3800 ng / mL, about 3850 ng / mL, about 3900 ng / mL, about 3950 ng / mL, about 4000 ng / mL, about 4050 ng / mL, about 4100 ng / mL, about 4150 ng / mL, about 4200 ng / mL, about 4250 ng / mL, about 4300 ng / mL, about 4350 ng / mL, about 4400 ng / mL, about 4450 ng / mL, about 4500 ng / mL, about 4550 ng / mL, about 4600 ng / mL, about 4650 ng / mL,about 4700 ng / mL, about 4750 ng / mL, about 4800 ng / mL, about 4850 ng / mL, about 4900 ng / mL, about 4950 ng / mL, about 5000 ng / mL, about 5100 ng / mL, about 5200 ng / mL, about 5300 ng / mL, about 5400 ng / mL, about 5500 ng / mL, about 5600 ng / mL, about 5700 ng / mL, about 5800 ng / mL, about 5900 ng / mL, about 6000 ng / mL, about 6500 ng / mL, about 7000 ng / mL, about 7500 ng / mL, about 8000 ng / mL, about 8500 ng / mL, about 9000 ng / mL, about 9500 ng / mL, about 10000 ng / mL, about 11000 ng / mL, about 12000 ng / mL, about 13000 ng / mL, about 14000 ng / mL, about 15000 ng / mL, about 16000 ng / mL, about 17000 ng / mL, about 18000 ng / mL, about 19000 ng / mL, or about 20000 ng / mL, or any range therebetween.

[0159] In some embodiments, the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is C maxabout 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, about 750 ng / mL, about 800 ng / mL, about 850 ng / mL, about 900 ng / mL, about 950 ng / mL, about 1000 ng / mL, about 1050 ng / mL, about 1100 ng / mL, about 1150 ng / mL, about 1200 ng / mL, about 1250 ng / mL, about 1300ng / mL, about 1350ng / mL, about 1400ng / mL, about 1450ng / mL, about 1500ng / mL, about 1550ng / mL, about 1600ng / mL, about 1650ng / mL, about 1700ng / mL, about 1750ng / mL, about 1800ng / mL, about 1850ng / mL, about 1900ng / mL, about 1950ng / mL, about 2000ng / mL, about 2050ng / mL, about 2100ng / mL, about 2150ng / mL, about 2200ng / mL, about 2250ng / mL, about 2300ng / mL, about 2350ng / mL, about 2400ng / mL mL, about 2450 ng / mL, about 2500 ng / mL, about 2550 ng / mL, about 2600 ng / mL, about 2650 ng / mL, about 2700 ng / mL, about 2750 ng / mL, about 2800 ng / mL, about 2850 ng / mL, about 2900 ng / mL, about 2950 ng / mL, about 3000 ng / mL, about 3050 ng / mL, about 3100 ng / mL, about 3150 ng / mL, about 3200 ng / mL, about 3250 ng / mL, about 3300 ng / mL, about 3350 ng / mL, about 3400 ng / mL, about 3450 ng / mL, about 3500 ng / mL, about 355 0 ng / mL, about 3600 ng / mL, about 3650 ng / mL, about 3700 ng / mL, about 3750 ng / mL, about 3800 ng / mL, about 3850 ng / mL, about 3900 ng / mL, about 3950 ng / mL, about 4000 ng / mL, about 4050 ng / mL, about 4100 ng / mL, about 4150 ng / mL, about 4200 ng / mL, about 4250 ng / mL, about 4300 ng / mL, about 4350 ng / mL, about 4400 ng / mL, about 4450 ng / mL, about 4500 ng / mL, about 4550 ng / mL, about 4600 ng / mL, about 4650 ng / mL,about 4700 ng / mL, about 4750 ng / mL, about 4800 ng / mL, about 4850 ng / mL, about 4900 ng / mL, about 4950 ng / mL, about 5000 ng / mL, about 5100 ng / mL, about 5200 ng / mL, about 5300 ng / mL, about 5400 ng / mL, about 5500 ng / mL, about 5600 ng / mL, about 5700 ng / mL, about 5800 ng / mL, about 5900 ng / mL, about 6000 ng / mL, about 6500 ng / mL, about 7000 ng / mL, about 7500 ng / mL, about 8000 ng / mL, about 8500 ng / mL, about 9000 ng / mL, about 9500 ng / mL, about 10000 ng / mL, about 11000 ng / mL, about 12000 ng / mL, about 13000 ng / mL, about 14000 ng / mL, about 15000 ng / mL, about 16000 ng / mL, about 17000 ng / mL, about 18000 ng / mL, about 19000 ng / mL, or about 20000 ng / mL, or any range therebetween.

[0160] In some embodiments, on day 7 of said administration in said subject in need thereof, the resulting plasma concentration of said β-lactam compound is C maxabout 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, about 750 ng / mL, about 800 ng / mL, about 850 ng / mL, about 900 ng / mL, about 950 ng / mL, about 1000 ng / mL, about 1050 ng / mL, about 1100 ng / mL, about 1150 ng / mL, about 1200 ng / mL, about 1250 ng / mL, about 1300ng / mL, about 1350ng / mL, about 1400ng / mL, about 1450ng / mL, about 1500ng / mL, about 1550ng / mL, about 1600ng / mL, about 1650ng / mL, about 1700ng / mL, about 1750ng / mL, about 1800ng / mL, about 1850ng / mL, about 1900ng / mL, about 1950ng / mL, about 2000ng / mL, about 2050ng / mL, about 2100ng / mL, about 2150ng / mL, about 2200ng / mL, about 2250ng / mL, about 2300ng / mL, about 2350ng / mL, about 2400ng / mL mL, about 2450 ng / mL, about 2500 ng / mL, about 2550 ng / mL, about 2600 ng / mL, about 2650 ng / mL, about 2700 ng / mL, about 2750 ng / mL, about 2800 ng / mL, about 2850 ng / mL, about 2900 ng / mL, about 2950 ng / mL, about 3000 ng / mL, about 3050 ng / mL, about 3100 ng / mL, about 3150 ng / mL, about 3200 ng / mL, about 3250 ng / mL, about 3300 ng / mL, about 3350 ng / mL, about 3400 ng / mL, about 3450 ng / mL, about 3500 ng / mL, about 355 0 ng / mL, about 3600 ng / mL, about 3650 ng / mL, about 3700 ng / mL, about 3750 ng / mL, about 3800 ng / mL, about 3850 ng / mL, about 3900 ng / mL, about 3950 ng / mL, about 4000 ng / mL, about 4050 ng / mL, about 4100 ng / mL, about 4150 ng / mL, about 4200 ng / mL, about 4250 ng / mL, about 4300 ng / mL, about 4350 ng / mL, about 4400 ng / mL, about 4450 ng / mL, about 4500 ng / mL, about 4550 ng / mL, about 4600 ng / mL, about 4650 ng / mL,about 4700 ng / mL, about 4750 ng / mL, about 4800 ng / mL, about 4850 ng / mL, about 4900 ng / mL, about 4950 ng / mL, about 5000 ng / mL, about 5100 ng / mL, about 5200 ng / mL, about 5300 ng / mL, about 5400 ng / mL, about 5500 ng / mL, about 5600 ng / mL, about 5700 ng / mL, about 5800 ng / mL, about 5900 ng / mL, about 6000 ng / mL, about 6500 ng / mL, about 7000 ng / mL, about 7500 ng / mL, about 8000 ng / mL, about 8500 ng / mL, about 9000 ng / mL, about 9500 ng / mL, about 10000 ng / mL, about 11000 ng / mL, about 12000 ng / mL, about 13000 ng / mL, about 14000 ng / mL, about 15000 ng / mL, about 16000 ng / mL, about 17000 ng / mL, about 18000 ng / mL, about 19000 ng / mL, or about 20000 ng / mL, or any range therebetween.

[0161] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on the first day of the administration is about 100 hr*ng / mL, about 150 hr*ng / mL, about 200 hr*ng / mL, about 250 hr*ng / mL, about 300 hr*ng / mL, about 350 hr*ng / mL, about 400 hr*ng / mL, about 450 hr*ng / mL, about 500 hr*ng / mL, about 550 hr*ng / mL, about 600 hr*ng / mL, about 650 hr*ng / mL, about 700 hr*ng / mL, about 750 hr*ng / mL, about 800 hr*ng / mL, about 850 hr*ng / mL, about 900 hr*ng / mL, about 910 hr*ng / mL, about 920 hr*ng / mL, about 930 hr*ng / mL, about 940 hr*ng / mL, about 950 hr*ng / mL, about 960 hr*ng / mL, about 970 hr*ng / mL, about 980 hr*ng / mL, about 1000 hr*ng / mL, about 1010 hr*ng / mL, about 1020 hr*ng / mL, about 1030 hr*ng / mL, about 1040 hr*ng / mL, about 1050 hr*ng / mL 0 hr*ng / mL, about 900 hr*ng / mL, about 950 hr*ng / mL, about 1000 hr*ng / mL, about 1050 hr*ng / mL, about 1100 hr*ng / mL, about 1150 hr*ng / mL, about 1200 hr*ng / mL, about 1250 hr*ng / mL, about 1300 hr*ng / mL, about 1350 hr*ng / mL, about 1400 hr*ng / mL, about 1450 hr*ng / mL, about 1500 hr*ng / mL, about 1550 hr*ng / mL, about 1600 hr*ng / mL, about 1650 hr*ng / mL, about 1700 hr*ng / mL, about 175 0 hr*ng / mL, about 1800 hr*ng / mL, about 1850 hr*ng / mL, about 1900 hr*ng / mL, about 1950 hr*ng / mL, about 2000 hr*ng / mL, about 2050 hr*ng / mL, about 2100 hr*ng / mL, about 2150 hr*ng / mL, about 2200 hr*ng / mL, about 2250 hr*ng / mL, about 2300 hr*ng / mL, about 2350 hr*ng / mL, about 2400 hr*ng / mL, about 2450 hr*ng / mL, about 2500 hr*ng / mL, about 2550 hr*ng / mL, about 2600 hr*ng / mL, about 2650 hr*ng / mL 3000 hr*ng / mL, about 3050 hr*ng / mL, about 3100 hr*ng / mL, about 3150 hr*ng / mL, about 3200 hr*ng / mL, about 3250 hr*ng / mL, about 3300 hr*ng / mL, about 3350 hr*ng / mL, about 3400 hr*ng / mL, about 3450 hr*ng / mL, about 3500 hr*ng / mL, about 3600 hr*ng / mL, about 3650 hr*ng / mL, about 3800 hr*ng / mL, about 3850 hr*ng / mL, about 3900 hr*ng / mL, about 3950 hr*ng / mL, about 3000 hr*ng / mL, about 3050 hr*ng / mL, about 3100 hr*ng / mL, about 3150 hr*ng / mL, about 3200 hr*ng / mL, about 3250 hr*ng / mL, about 3300 hr*ng / mL, about 3350 hr*ng / mL, about 3400 hr*ng / mL, about 3450 hr*ng / mL, about 3500 hr*ng / mL,about 3550 hr*ng / mL, about 3600 hr*ng / mL, about 3650 hr*ng / mL, about 3700 hr*ng / mL, about 3750 hr*ng / mL, about 3800 hr*ng / mL, about 3850 hr*ng / mL, about 3900 hr*ng / mL, about 3950 hr*ng / mL, about 4000 hr*ng / mL, about 4050 hr*ng / mL, about 4100 hr*ng / mL, about 4150 hr*ng / mL, about 4200 hr*ng / mL, about 4250 hr*ng / mL L, about 4300 hr*ng / mL, about 4350 hr*ng / mL, about 4400 hr*ng / mL, about 4450 hr*ng / mL, about 4500 hr*ng / mL, about 4550 hr*ng / mL, about 4600 hr*ng / mL, about 4650 hr*ng / mL, about 4700 hr*ng / mL, about 4750 hr*ng / mL, about 4800 hr*ng / mL, about 4850 hr*ng / mL, about 4900 hr*ng / mL, about 4950 hr*ng / mL, about 5000 hr*ng / mL / mL, about 5100 hr*ng / mL, about 5200 hr*ng / mL, about 5300 hr*ng / mL, about 5400 hr*ng / mL, about 5500 hr*ng / mL, about 5600 hr*ng / mL, about 5700 hr*ng / mL, about 5800 hr*ng / mL, about 5900 hr*ng / mL, about 6000 hr*ng / mL, about 6500 hr*ng / mL, about 7000 hr*ng / mL, about 7500 hr*ng / mL, about 8000 hr*ng / mL, about 8500 hr*ng / mL ng / mL, about 9000 hr*ng / mL, about 9500 hr*ng / mL, about 10000 hr*ng / mL, about 11000 hr*ng / mL, about 12000 hr*ng / mL, about 13000 hr*ng / mL, about 14000 hr*ng / mL, about 15000 hr*ng / mL, about 16000 hr*ng / mL, about 17000 hr*ng / mL, about 18000 hr*ng / mL, about 19000 hr*ng / mL, or about 20000 hr*ng / mL, or any range therebetween.

[0162] In some embodiments, the AUC of the plasma concentration of the β-lactam compound obtained in the comparable subjects on day 7 of the administration is about 100 hr*ng / mL, about 150 hr*ng / mL, about 200 hr*ng / mL, about 250 hr*ng / mL, about 300 hr*ng / mL, about 350 hr*ng / mL, about 400 hr*ng / mL, about 450 hr*ng / mL, about 500 hr*ng / mL, about 550 hr*ng / mL, about 600 hr*ng / mL, about 650 hr*ng / mL, about 700 hr*ng / mL, about 750 hr*ng / mL, about 800 hr*ng / mL, about 850 hr*ng / mL, about 900 hr*ng / mL, about 910 hr*ng / mL, about 920 hr*ng / mL, about 930 hr*ng / mL, about 940 hr*ng / mL, about 950 hr*ng / mL, about 960 hr*ng / mL, about 970 hr*ng / mL, about 980 hr*ng / mL, about 1000 hr*ng / mL, about 1010 hr*ng / mL, about 1020 hr*ng / mL, about 1030 hr*ng / mL, about 1040 hr*ng / mL, about 1050 hr*ng / mL 0 hr*ng / mL, about 900 hr*ng / mL, about 950 hr*ng / mL, about 1000 hr*ng / mL, about 1050 hr*ng / mL, about 1100 hr*ng / mL, about 1150 hr*ng / mL, about 1200 hr*ng / mL, about 1250 hr*ng / mL, about 1300 hr*ng / mL, about 1350 hr*ng / mL, about 1400 hr*ng / mL, about 1450 hr*ng / mL, about 1500 hr*ng / mL, about 1550 hr*ng / mL, about 1600 hr*ng / mL, about 1650 hr*ng / mL, about 1700 hr*ng / mL, about 175 0 hr*ng / mL, about 1800 hr*ng / mL, about 1850 hr*ng / mL, about 1900 hr*ng / mL, about 1950 hr*ng / mL, about 2000 hr*ng / mL, about 2050 hr*ng / mL, about 2100 hr*ng / mL, about 2150 hr*ng / mL, about 2200 hr*ng / mL, about 2250 hr*ng / mL, about 2300 hr*ng / mL, about 2350 hr*ng / mL, about 2400 hr*ng / mL, about 2450 hr*ng / mL, about 2500 hr*ng / mL, about 2550 hr*ng / mL, about 2600 hr*ng / mL, about 2650 hr*ng / mL 3000 hr*ng / mL, about 3050 hr*ng / mL, about 3100 hr*ng / mL, about 3150 hr*ng / mL, about 3200 hr*ng / mL, about 3250 hr*ng / mL, about 3300 hr*ng / mL, about 3350 hr*ng / mL, about 3400 hr*ng / mL, about 3450 hr*ng / mL, about 3500 hr*ng / mL, about 3600 hr*ng / mL, about 3650 hr*ng / mL, about 3800 hr*ng / mL, about 3850 hr*ng / mL, about 3900 hr*ng / mL, about 3950 hr*ng / mL, about 3000 hr*ng / mL, about 3050 hr*ng / mL, about 3100 hr*ng / mL, about 3150 hr*ng / mL, about 3200 hr*ng / mL, about 3250 hr*ng / mL, about 3300 hr*ng / mL, about 3350 hr*ng / mL, about 3400 hr*ng / mL, about 3450 hr*ng / mL, about 3500 hr*ng / mL,about 3550 hr*ng / mL, about 3600 hr*ng / mL, about 3650 hr*ng / mL, about 3700 hr*ng / mL, about 3750 hr*ng / mL, about 3800 hr*ng / mL, about 3850 hr*ng / mL, about 3900 hr*ng / mL, about 3950 hr*ng / mL, about 4000 hr*ng / mL, about 4050 hr*ng / mL, about 4100 hr*ng / mL, about 4150 hr*ng / mL, about 4200 hr*ng / mL, about 4250 hr*ng / mL L, about 4300 hr*ng / mL, about 4350 hr*ng / mL, about 4400 hr*ng / mL, about 4450 hr*ng / mL, about 4500 hr*ng / mL, about 4550 hr*ng / mL, about 4600 hr*ng / mL, about 4650 hr*ng / mL, about 4700 hr*ng / mL, about 4750 hr*ng / mL, about 4800 hr*ng / mL, about 4850 hr*ng / mL, about 4900 hr*ng / mL, about 4950 hr*ng / mL, about 5000 hr*ng / mL / mL, about 5100 hr*ng / mL, about 5200 hr*ng / mL, about 5300 hr*ng / mL, about 5400 hr*ng / mL, about 5500 hr*ng / mL, about 5600 hr*ng / mL, about 5700 hr*ng / mL, about 5800 hr*ng / mL, about 5900 hr*ng / mL, about 6000 hr*ng / mL, about 6500 hr*ng / mL, about 7000 hr*ng / mL, about 7500 hr*ng / mL, about 8000 hr*ng / mL, about 8500 hr*ng / mL ng / mL, about 9000 hr*ng / mL, about 9500 hr*ng / mL, about 10000 hr*ng / mL, about 11000 hr*ng / mL, about 12000 hr*ng / mL, about 13000 hr*ng / mL, about 14000 hr*ng / mL, about 15000 hr*ng / mL, about 16000 hr*ng / mL, about 17000 hr*ng / mL, about 18000 hr*ng / mL, about 19000 hr*ng / mL, or about 20000 hr*ng / mL, or any range therebetween.

[0163] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the subject in need thereof on the first day of the administration is about 100 hr*ng / mL, about 150 hr*ng / mL, about 200 hr*ng / mL, about 250 hr*ng / mL, about 300 hr*ng / mL, about 350 hr*ng / mL, about 400 hr*ng / mL, about 450 hr*ng / mL, about 500 hr*ng / mL, about 550 hr*ng / mL, about 600 hr*ng / mL, about 650 hr*ng / mL, about 700 hr*ng / mL, about 750 hr*ng / mL, about 80 ... L, about 850 hr*ng / mL, about 900 hr*ng / mL, about 950 hr*ng / mL, about 1000 hr*ng / mL, about 1050 hr*ng / mL, about 1100 hr*ng / mL, about 1150 hr*ng / mL, about 1200 hr*ng / mL, about 1250 hr*ng / mL, about 1300 hr*ng / mL, about 1350 hr*ng / mL, about 1400 hr*ng / mL, about 1450 hr*ng / mL, about 1500 hr*ng / mL, about 1550 hr*ng / mL, about 1600 hr*ng / mL, about 1650 hr*ng / mL, about 1700 hr*ng / mL, about 1750hr*ng / mL, about 1800hr*ng / mL, about 1850hr*ng / mL, about 1900hr*ng / mL, about 1950hr*ng / mL, about 2000hr*ng / mL, about 2050hr*ng / mL, about 2100hr*ng / mL, about 2150hr*ng / mL, about 2200hr*ng / mL, about 2250hr*ng / mL, about 2300hr*ng / mL, about 2350hr*ng / mL, about 2400hr*ng / mL, about 2450hr*ng / mL, about 2500hr*ng / mL, about 2550hr*ng / mL, about 2600hr*ng / mL hr*ng / mL, about 2650hr*ng / mL, about 2700hr*ng / mL, about 2750hr*ng / mL, about 2800hr*ng / mL, about 2850hr*ng / mL, about 2900hr*ng / mL, about 2950hr*ng / mL, about 3000hr*ng / mL, about 3050hr*ng / mL, about 3100hr*ng / mL, about 3150hr*ng / mL, about 3200hr*ng / mL, about 3250hr*ng / mL, about 3300hr*ng / mL, about 3350hr*ng / mL, about 3400hr*ng / mL, about 3450hr*ng / mL,about 3500 hr*ng / mL, about 3550 hr*ng / mL, about 3600 hr*ng / mL, about 3650 hr*ng / mL, about 3700 hr*ng / mL, about 3750 hr*ng / mL, about 3800 hr*ng / mL, about 3850 hr*ng / mL, about 3900 hr*ng / mL, about 3950 hr*ng / mL, about 4000 hr*ng / mL, about 4050 hr*ng / mL, about 4100 hr*ng / mL, about 4150 hr*ng / mL, about 4200 hr*ng / mL, about 4250hr*ng / mL, about 4300hr*ng / mL, about 4350hr*ng / mL, about 4400hr*ng / mL, about 4450hr*ng / mL, about 4500hr*ng / mL, about 4550hr*ng / mL, about 4600hr*ng / mL, about 4650hr*ng / mL, about 4700hr*ng / mL, about 4750hr*ng / mL, about 4800hr*ng / mL, about 4850hr*ng / mL, about 4900hr*ng / mL, about 4950hr*ng / mL, about 50 00hr*ng / mL, about 5100hr*ng / mL, about 5200hr*ng / mL, about 5300hr*ng / mL, about 5400hr*ng / mL, about 5500hr*ng / mL, about 5600hr*ng / mL, about 5700hr*ng / mL, about 5800hr*ng / mL, about 5900hr*ng / mL, about 6000hr*ng / mL, about 6500hr*ng / mL, about 7000hr*ng / mL, about 7500hr*ng / mL, about 8000hr*ng / mL, about 8500hr*ng / mL hr*ng / mL, about 9000 hr*ng / mL, about 9500 hr*ng / mL, about 10000 hr*ng / mL, about 11000 hr*ng / mL, about 12000 hr*ng / mL, about 13000 hr*ng / mL, about 14000 hr*ng / mL, about 15000 hr*ng / mL, about 16000 hr*ng / mL, about 17000 hr*ng / mL, about 18000 hr*ng / mL, about 19000 hr*ng / mL, or about 20000 hr*ng / mL, or any range therebetween.

[0164] In some embodiments, the AUC of the resulting plasma concentration of the β-lactam compound in the subject in need thereof on day 7 of the dosing is about 100 hr*ng / mL, about 150 hr*ng / mL, about 200 hr*ng / mL, about 250 hr*ng / mL, about 300 hr*ng / mL, about 350 hr*ng / mL, about 400 hr*ng / mL, about 450 hr*ng / mL, about 500 hr*ng / mL, about 550 hr*ng / mL, about 600 hr*ng / mL, about 650 hr*ng / mL, about 700 hr*ng / mL, about 750 hr*ng / mL, about 80 ... L, about 850 hr*ng / mL, about 900 hr*ng / mL, about 950 hr*ng / mL, about 1000 hr*ng / mL, about 1050 hr*ng / mL, about 1100 hr*ng / mL, about 1150 hr*ng / mL, about 1200 hr*ng / mL, about 1250 hr*ng / mL, about 1300 hr*ng / mL, about 1350 hr*ng / mL, about 1400 hr*ng / mL, about 1450 hr*ng / mL, about 1500 hr*ng / mL, about 1550 hr*ng / mL, about 1600 hr*ng / mL, about 1650 hr*ng / mL, about 1700 hr*ng / mL, about 1750hr*ng / mL, about 1800hr*ng / mL, about 1850hr*ng / mL, about 1900hr*ng / mL, about 1950hr*ng / mL, about 2000hr*ng / mL, about 2050hr*ng / mL, about 2100hr*ng / mL, about 2150hr*ng / mL, about 2200hr*ng / mL, about 2250hr*ng / mL, about 2300hr*ng / mL, about 2350hr*ng / mL, about 2400hr*ng / mL, about 2450hr*ng / mL, about 2500hr*ng / mL, about 2550hr*ng / mL, about 2600hr*ng / mL hr*ng / mL, about 2650hr*ng / mL, about 2700hr*ng / mL, about 2750hr*ng / mL, about 2800hr*ng / mL, about 2850hr*ng / mL, about 2900hr*ng / mL, about 2950hr*ng / mL, about 3000hr*ng / mL, about 3050hr*ng / mL, about 3100hr*ng / mL, about 3150hr*ng / mL, about 3200hr*ng / mL, about 3250hr*ng / mL, about 3300hr*ng / mL, about 3350hr*ng / mL, about 3400hr*ng / mL, about 3450hr*ng / mL,about 3500 hr*ng / mL, about 3550 hr*ng / mL, about 3600 hr*ng / mL, about 3650 hr*ng / mL, about 3700 hr*ng / mL, about 3750 hr*ng / mL, about 3800 hr*ng / mL, about 3850 hr*ng / mL, about 3900 hr*ng / mL, about 3950 hr*ng / mL, about 4000 hr*ng / mL, about 4050 hr*ng / mL, about 4100 hr*ng / mL, about 4150 hr*ng / mL, about 4200 hr*ng / mL, about 4250hr*ng / mL, about 4300hr*ng / mL, about 4350hr*ng / mL, about 4400hr*ng / mL, about 4450hr*ng / mL, about 4500hr*ng / mL, about 4550hr*ng / mL, about 4600hr*ng / mL, about 4650hr*ng / mL, about 4700hr*ng / mL, about 4750hr*ng / mL, about 4800hr*ng / mL, about 4850hr*ng / mL, about 4900hr*ng / mL, about 4950hr*ng / mL, about 50 00hr*ng / mL, about 5100hr*ng / mL, about 5200hr*ng / mL, about 5300hr*ng / mL, about 5400hr*ng / mL, about 5500hr*ng / mL, about 5600hr*ng / mL, about 5700hr*ng / mL, about 5800hr*ng / mL, about 5900hr*ng / mL, about 6000hr*ng / mL, about 6500hr*ng / mL, about 7000hr*ng / mL, about 7500hr*ng / mL, about 8000hr*ng / mL, about 8500hr*ng / mL hr*ng / mL, about 9000 hr*ng / mL, about 9500 hr*ng / mL, about 10000 hr*ng / mL, about 11000 hr*ng / mL, about 12000 hr*ng / mL, about 13000 hr*ng / mL, about 14000 hr*ng / mL, about 15000 hr*ng / mL, about 16000 hr*ng / mL, about 17000 hr*ng / mL, about 18000 hr*ng / mL, about 19000 hr*ng / mL, or about 20000 hr*ng / mL, or any range therebetween.

[0165] Other effects of the method The methods of the present disclosure may result in one or more additional effects on the subject in need thereof.

[0166] In some embodiments, said administering results in a longer half-life of said β-lactam compound in said subject in need thereof over said time period compared to a comparable subject administered said pharmaceutically effective amount of said β-lactam compound without administering probenecid.

[0167] In some embodiments, the administering results in a half-life of the β-lactam compound in the subject in need thereof that is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, or about 500% longer over the time period as compared to a comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid.

[0168] In some embodiments, said administering results in said β-lactam compound exceeding a minimum inhibitory concentration (MIC) in said subject in need thereof for a longer period of time during said period of time compared to a comparable subject administered said pharmaceutically effective amount of said β-lactam compound without administering probenecid.

[0169] In some embodiments, the administering results in the beta-lactam compound being above the MIC in the subject in need thereof for about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, or about 500% longer during the time period compared to a comparable subject administered the pharmaceutically effective amount of the beta-lactam compound without probenecid.

[0170] In some embodiments, the administration of probenecid, or a pharmaceutically acceptable salt thereof, does not substantially increase the elimination rate of the β-lactam compound, or a pharmaceutically acceptable salt thereof, in the subject in need thereof.

[0171] In some embodiments, the elimination rate of the β-lactam compound, or a pharmaceutically acceptable salt thereof, in the subject in need thereof is about 150% or less, about 120% or less, about 110% or less, about 105% or less, about 103% or less, or about 101% or less, compared to the comparable subject.

[0172] In some embodiments, the elimination rate of the β-lactam compound or a pharmaceutically acceptable salt thereof in the subject in need thereof is about the same as that in the comparable subject.

[0173] In some embodiments, administration of probenecid or a pharmaceutically acceptable salt thereof enhances the absorption rate of the β-lactam compound or a pharmaceutically acceptable salt thereof in the subject in need thereof.

[0174] In some embodiments, the absorption rate of the β-lactam compound or a pharmaceutically acceptable salt thereof in the subject in need thereof is higher compared to the comparable subject, by an amount ranging from about 2% to about 100%, about 4% to about 80%, about 6% to about 60%, about 8% to about 40%, about 10% to about 30%, about 12% to about 25%, or about 15% to about 20%.

[0175] Subjects and diseases treated In some embodiments, the subject in need thereof is an animal. In some embodiments, the subject in need thereof is a human.

[0176] In some embodiments, the subject in need thereof is a human 18 years of age or older.

[0177] In some embodiments, the subject in need thereof is a human less than 18 years old.

[0178] In some embodiments, the disease is associated with an increase or decrease in the population of one or more microorganisms (eg, bacteria) in the subject.

[0179] In some embodiments, the disease is associated with an increase in the population of one or more microorganisms (e.g., bacteria) in the subject. In some embodiments, the methods of the present disclosure result in a decrease in the population of one or more microorganisms (e.g., bacteria) in the subject.

[0180] In some embodiments, the disease is associated with a decrease in the population of one or more microorganisms (e.g., bacteria) in a subject. In some embodiments, the methods of the present disclosure result in an increase in the population of one or more microorganisms (e.g., bacteria) in a subject.

[0181] In some embodiments, the disease is associated with an increase or decrease in the population of one or more bacteria selected from the group consisting of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides coprocola, Prevotella copri, Porphyromonas asaccharolytica, and Prevotella bivia, or any organism in the following genera: Succinivibrio, Alistipes, Prevotella, Paraprevotella, Parabacteroides, and Odoribacter.

[0182] In some embodiments, the disease is associated with an increase or decrease in a population of one or more bacteria selected from the group consisting of Staphylococcus epidermidis, Streptococcus pneumonia, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pyogenes.

[0183] In some embodiments, the disease is associated with an increase or decrease in the population of one or more bacteria selected from the group consisting of Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Haemophilus influenza, Haemophilus parainfluenzae, Klebsiella oxytoca, Moraxella catarrhalis, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providencia stuartiihe, and Serratia marcescens.

[0184] In some embodiments, the disease is associated with an increase or decrease in a population of one or more bacteria selected from the group consisting of Bacteroides vulgatus, Clostridium perfringens, and Fusobacterium spp.

[0185] In some embodiments, the disease is associated with an infection. In some embodiments, the infection is a gram-negative infection. In some embodiments, the infection is a gram-positive infection.

[0186] In some embodiments, the infection is resistant to one or more antibiotics when administered in the absence of probenecid or a pharmaceutically acceptable salt thereof.

[0187] In some embodiments, the infection is resistant to one or more β-lactam compounds when administered in the absence of probenecid or a pharmaceutically acceptable salt thereof.

[0188] In some embodiments, the disease is uncomplicated urinary tract infection, complicated urinary tract infection, complicated intra-abdominal infection, uncomplicated intra-abdominal infection, pneumonia, otitis media, sinusitis, gonococcal urethritis, pelvic inflammatory disease, prostatitis, bone infection, joint infection, diabetic foot infection, and infectious diarrhea.

[0189] In some embodiments, the disease is associated with (eg, caused by) an alteration in the microbiome in the subject.

[0190] In some embodiments, the disease is associated with (eg, caused by) an alteration in the microbiome in the human subject.

[0191] In some embodiments, the disease is a neurodegenerative disease.

[0192] In some embodiments, the disease is amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, schizophrenia, or Huntington's disease.

[0193] In some embodiments, the disease is Alzheimer's disease.It is noted that probenecid has been found to increase the concentration of beta-lactam compounds in cerebrospinal fluid (Ralph G. Dacey and Merle A. Sande, Antimicrobial Agents and Chemotherapy 6:437-441 (1974)). Recently, the bacterial pathogen Porphyromonas gingivalis has been found in the brain to be associated with pathological lesions associated with Alzheimer's disease (Dominy et al., Sci. Adv. 5:eaau3333 (2019), and thiopentane is active against this bacterium (Lois M. Ednie and Peter C. Appelbaum, Antimicrobial Agents and Chemotherapy 53:2163-2170 (2009)). Without wishing to be bound by theory, it is understood that when a β-lactam compound (e.g., Compound III-2b) is administered with probenecid, more effective treatment of brain infection with this organism can result, relative to treatment with thiopentane alone.

[0194] In some embodiments, the disease is cancer.

[0195] In some embodiments, the cancer is a solid cancer, such as ovarian cancer, breast cancer, head and neck cancer, kidney cancer, bladder cancer, hepatocellular carcinoma, colorectal cancer, or lymphoma, or any combination thereof.

[0196] In some embodiments, the cancer is a sarcoma or carcinoma, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary Adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung cancer, small cell lung cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma.

[0197] In some embodiments, the cancer is a leukemia, such as acute lymphocytic leukemia and acute myeloid leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia); or chronic leukemia (chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia).

[0198] In some embodiments, the cancer is polycythemia vera, lymphoma (Hodgkin's and non-Hodgkin's), multiple myeloma, Waldenstrom's macroglobulinemia, or heavy chain disease.

[0199] In some embodiments, the disease is inflammatory bowel disease.

[0200] In some embodiments, the inflammatory bowel disease is Crohn's disease, ulcerative colitis, indeterminate colitis, irritable bowel syndrome, microscopic colitis, idiopathic colitis, or Behcet's disease.

[0201] β-lactam compounds In some embodiments, the β-lactam compound is monobactam or a prodrug thereof.

[0202] In some embodiments, the β-lactam compound is aztreonam, tigemonam, carumonam, nocardin A, a prodrug thereof, an analog thereof, or a derivative thereof.

[0203] In some embodiments, the β-lactam compound is a penem, carbapenem, clavulanate, or a prodrug thereof.

[0204] In some embodiments, the β-lactam compound is penicillin, benzathine penicillin, procaine penicillin, penicillin V, propicillin, pheneticillin, azidocillin, clomethicillin, penacillin, cloxacillin (e.g., dicloxacillin or flucloxacillin), oxacillin, nafcillin, methicillin, amoxicillin, ampicillin (e.g., pivampicillin, hetacillin, bacampicillin, metamcillin, talampicillin), epicillin, ticarcillin, carbenicillin, carbocillin, temocillin, piperacillin, azlocillin, mezlocillin, mecillin (e.g., pivampicillin), sulbenicillin, a pharmaceutically acceptable salt thereof, a prodrug thereof, an analog thereof, or a derivative thereof.

[0205] In some embodiments, the β-lactam compound is a penem, carbapenem, or a prodrug thereof.

[0206] In some embodiments, the β-lactam compound is thiopenem, oxypenem, aminopenem, alkylpenem, arylpenem, or a prodrug thereof.

[0207] In some embodiments, the β-lactam compound is ertapenem, an anti-Pseudomonas aeruginosa carbapenem (e.g., doripenem, imipenem, meropenem), biapenem, panipenem, sulopenem, tebipenem, faropenem, a pharmaceutically acceptable salt thereof, a prodrug thereof, an analog thereof, or a derivative thereof.

[0208] In some embodiments, the β-lactam compound is a cephem, a carbacephem, an oxacephem, or a prodrug thereof.

[0209] In some embodiments, the β-lactam compound is cefazolin, cephalexin, cefadroxil, cefpirin, cefazolin, cefazolin, cefotaxime, cefotaxime, cefuroxime, cefotaxime, ceftriaxone, cefaclor, cefotetan, cephalosporins (e.g., cefoxitin, cefprozil, cefuroxime, cefuroxime acetoxyethyl, cefmandole, cefminox, cefonicid, cefoperazone, cefotaxime ... azole), carbacephems (e.g. loracarb), cefixime, ceftriaxone, anti-Pseudomonas aeruginosa (e.g. ceftazidime, cefoperazone), cefdinir, cefcaprine, cefodoxime, ceftizoxime, cefmenoxime, cefotaxime, cefpiramide, cefpodoxime, ceftibuten, cefditoren, cefetamet, cefdizime, cefimizolin, cefsulodin, cefditoren, ceftiolin, oxacephems (e.g. flumoxef, latamoxef), cefepime, cefazolin, cefpirome, ceftriaxone, ceftaroline fosamil, ceftolozane, ceftobiprole, ceftiofur, cefquinome, cefovecin, pharmaceutically acceptable salts thereof, prodrugs thereof, analogs thereof or derivatives thereof.

[0210] In some embodiments, the β-lactam compound is thiopenem or a prodrug thereof.

[0211] In some embodiments, the β-lactam compound has formula (I): Its pharmaceutically acceptable salt, prodrug, analog or derivative thereof, wherein R 1 is H or optionally substituted alkyl.

[0212] In some embodiments, the β-lactam compound has formula (Ia): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0213] In some embodiments, the β-lactam compound has formula (Ib): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0214] In some embodiments, R 1 For H.

[0215] In some embodiments, the β-lactam compound has formula (II): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0216] In some embodiments, the β-lactam compound has formula (IIa): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0217] In some embodiments, the β-lactam compound has formula (IIb): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0218] In some embodiments, R 1 is an optionally substituted alkyl group.

[0219] In some embodiments, the β-lactam compound has any one of formula (III), (IIIa), and (IIIb): Its pharmaceutically acceptable salt, prodrug, analog or derivative thereof, wherein R 2 is H or optionally substituted alkyl.

[0220] In some embodiments, the β-lactam compound is selected from: Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0221] In some embodiments, the β-lactam compound is selected from: Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0222] In some embodiments, the β-lactam compound is selected from (Compound III-2b; also known as Etzadroxil), Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0223] In some embodiments, the β-lactam compound is (Compound III-2b; also known as Sulopenem Etzadroxil).

[0224] In some embodiments, the β-lactam compound has any one of formula (IV), (IVa), and (IVb): Its pharmaceutically acceptable salt, prodrug, analog or derivative thereof, wherein R 3 is H or optionally substituted alkyl.

[0225] In some embodiments, R 3 It is a C2-C8 alkyl group.

[0226] In some embodiments, R 3 It is CH2CH3, CH2CH2CH3 or CH2CH(CH3)2.

[0227] Administration of beta-lactam compounds and probenecid In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered simultaneously.

[0228] In some embodiments, both the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered by enteral administration.

[0229] In some embodiments, the enteral administration is oral administration.

[0230] In some embodiments, an oral co-formulation comprising the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof is administered.

[0231] In some embodiments, a tablet comprising the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof is administered.

[0232] In some embodiments, the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, are both administered in separate oral formulations.

[0233] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are both administered in separate tablets.

[0234] In some embodiments, both the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered by parenteral administration.

[0235] In some embodiments, the parenteral administration is intravenous administration.

[0236] In some embodiments, the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, are administered in a co-formulation.

[0237] In some embodiments, the co-formulation is administered to the subject once or more daily.

[0238] In some embodiments, the co-formulation is an oral co-formulation (eg, a tablet).

[0239] In some embodiments, the oral co-formulation comprises: 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof; and 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg of probenecid or a pharmaceutically acceptable salt thereof.

[0240] In some embodiments, the oral co-formulation comprises about 500 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof and about 500 mg of probenecid or a pharmaceutically acceptable salt thereof.

[0241] In some embodiments, the oral co-formulation is administered to the subject once a day, twice a day, three times a day, or four times a day for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 14 days, about 21 days, or about 28 days.

[0242] In some embodiments, the oral co-formulation is administered to the subject twice daily for about 5 days.

[0243] In some embodiments, the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, are administered in separate formulations.

[0244] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered simultaneously, sequentially or alternatingly.

[0245] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered simultaneously.

[0246] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered sequentially.

[0247] In some embodiments, the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, are administered close in time.

[0248] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered prior to administration of probenecid or a pharmaceutically acceptable salt thereof.

[0249] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered prior to administration of the β-lactam compound or a pharmaceutically acceptable salt thereof.

[0250] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered alternately.

[0251] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once or more daily in a daily dose ranging from about 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg.

[0252] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose of about 500 mg.

[0253] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once or more daily in a daily dose ranging from about 50 mg to about 10 g, about 100 mg to about 5 g, about 200 mg to about 3 g, about 400 mg to about 2 g, about 600 mg to about 1.5 g, about 800 mg to about 1.2 g, or about 900 mg to about 1.1 g.

[0254] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose of about 1 g.

[0255] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once or more daily, with a daily dose ranging from about 100 mg to about 10 g, about 200 mg to about 5 g, about 500 mg to about 3 g, about 800 mg to about 2.5 g, about 1 g to about 2 g, about 1.2 g to about 1.8 g, or about 1.4 g to about 1.6 g.

[0256] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose of about 1.5 g.

[0257] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered once daily.

[0258] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered twice daily.

[0259] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered three or more times daily.

[0260] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered continuously.

[0261] In some embodiments, the administration of the β-lactam compound or a pharmaceutically acceptable salt thereof continues for more than about 1 day.

[0262] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered for about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 14 days, or about 30 days.

[0263] In some embodiments, the β-lactam compound, or a pharmaceutically acceptable salt thereof, is administered with one or more drug holidays.

[0264] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered without any drug holiday.

[0265] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered by enteral administration.

[0266] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered by oral administration or rectal administration.

[0267] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered by oral administration.

[0268] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered parenterally.

[0269] In some embodiments, the β-lactam compound or a pharmaceutically acceptable salt thereof is administered by intravenous administration. In some embodiments, an injectable formulation of the β-lactam compound or a pharmaceutically acceptable salt thereof is administered to the subject.

[0270] In some embodiments, the injectable formulation is an intravenous infusion.

[0271] In some embodiments, the injectable formulation contains about 50 mg to about 10 g, about 100 mg to about 5 g, about 200 mg to about 3 g, about 400 mg to about 2 g, about 600 mg to about 1.5 g, about 800 mg to about 1.2 g, or about 900 mg to about 1.1 g of the β-lactam compound or a pharmaceutically acceptable salt thereof.

[0272] In some embodiments, the injectable formulation contains about 1 g of the β-lactam compound or a pharmaceutically acceptable salt thereof.

[0273] In some embodiments, the injectable formulation is administered to the subject by intravenous infusion over about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 6 hours, or about 12 hours.

[0274] In some embodiments, the injectable formulation is administered to the subject by intravenous infusion over about 3 hours.

[0275] In some embodiments, the injectable formulation is administered to the subject once every 6 hours, once every 12 hours, once every 24 hours, once every hour, or once every 48 hours for about 1 day to about 30 days, about 2 days to about 28 days, about 3 days to about 24 days, about 4 days to about 21 days, about 5 days to about 18 days, about 6 days to about 15 days, or about 7 days to about 14 days.

[0276] In some embodiments, the injectable formulation is administered to the subject once every 24 hours for about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

[0277] In some embodiments, the subject has renal impairment, and wherein: The injectable formulation comprises about 10 mg to about 2 g, about 25 mg to about 1 g, about 40 mg to about 500 mg, about 50 mg to about 450 mg, about 100 mg to about 400 mg, about 150 mg to about 350 mg, about 200 mg to about 300 mg, about 225 mg to about 275 mg, or about 240 mg to about 260 mg of the beta-lactam compound or a pharmaceutically acceptable salt thereof; administering the injectable formulation to the subject by intravenous infusion over about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 6 hours, or about 12 hours; and The injectable formulation is administered to the subject once every 6 hours, once every 12 hours, once every 24 hours, once every hour, or once every 48 hours.

[0278] In some embodiments, the subject has renal impairment, and wherein: The injectable formulation comprises about 250 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof; The injectable formulation is administered to the subject by intravenous infusion once every 24 hours over about 3 hours.

[0279] In some embodiments, the subject in need thereof does not fast for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days prior to administration of the β-lactam compound or a pharmaceutically acceptable salt thereof.

[0280] In some embodiments, the subject in need thereof fasts for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days prior to administration of the β-lactam compound or a pharmaceutically acceptable salt thereof.

[0281] In some embodiments, the subject in need thereof does not fast for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days after administration of the β-lactam compound or a pharmaceutically acceptable salt thereof.

[0282] In some embodiments, following administration of the β-lactam compound or a pharmaceutically acceptable salt thereof, the subject in need thereof fasts for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days.

[0283] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose ranging from about 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg.

[0284] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose of about 500 mg.

[0285] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once or more daily in a daily dose ranging from about 50 mg to about 10 g, about 100 mg to about 5 g, about 200 mg to about 3 g, about 400 mg to about 2 g, about 600 mg to about 1.5 g, about 800 mg to about 1.2 g, or about 900 mg to about 1.1 g.

[0286] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose of about 1 g.

[0287] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once or more daily, with a daily dose ranging from about 100 mg to about 10 g, about 200 mg to about 5 g, about 500 mg to about 3 g, about 800 mg to about 2.5 g, about 1 g to about 2 g, about 1.2 g to about 1.8 g, or about 1.4 g to about 1.6 g.

[0288] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once or more daily at a daily dose of about 1.5 g.

[0289] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered once daily.

[0290] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered twice daily.

[0291] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered three or more times daily.

[0292] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered continuously.

[0293] In some embodiments, the administration of probenecid or a pharmaceutically acceptable salt thereof continues for more than about 1 day.

[0294] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered for about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 14 days, or about 30 days.

[0295] In some embodiments, probenecid, or a pharmaceutically acceptable salt thereof, is administered with one or more drug holidays.

[0296] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered without any drug holiday.

[0297] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered by enteral administration.

[0298] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered by oral administration or rectal administration.

[0299] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered by oral administration.

[0300] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered parenterally.

[0301] In some embodiments, probenecid or a pharmaceutically acceptable salt thereof is administered by intravenous administration.

[0302] In some embodiments, the subject in need thereof does not fast for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days prior to administration of probenecid or a pharmaceutically acceptable salt thereof.

[0303] In some embodiments, the subject in need thereof fasts for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days prior to administration of probenecid or a pharmaceutically acceptable salt thereof.

[0304] In some embodiments, following administration of probenecid or a pharmaceutically acceptable salt thereof, the subject in need thereof does not fast for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days.

[0305] In some embodiments, following administration of probenecid or a pharmaceutically acceptable salt thereof, the subject in need thereof fasts for about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 2 days, about 5 days, or about 10 days.

[0306] Alternative uses of β-lactam compounds and probenecid In some aspects, the present disclosure provides a β-lactam compound or a pharmaceutically acceptable salt thereof, in combination with probenecid or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0307] In some aspects, the present disclosure provides probenecid or a pharmaceutically acceptable salt thereof, in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0308] In some aspects, the present disclosure provides a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0309] In some aspects, the present disclosure provides use of a β-lactam compound in combination with probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0310] In some aspects, the present disclosure provides use of probenecid in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0311] In some aspects, the present disclosure provides use of a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof are administered to the subject by the same route of administration.

[0312] In some aspects, the present disclosure provides a β-lactam compound or a pharmaceutically acceptable salt thereof, in combination with probenecid or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease, wherein: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0313] In some aspects, the present disclosure provides probenecid or a pharmaceutically acceptable salt thereof, in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease, wherein: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0314] In some aspects, the present disclosure provides a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease, wherein: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0315] In some aspects, the present disclosure provides use of a β-lactam compound or a pharmaceutically acceptable salt thereof in combination with probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease, wherein administration of the medicament to a subject in need thereof over a period of time results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0316] In some aspects, the present disclosure provides the use of probenecid or a pharmaceutically acceptable salt thereof in combination with a β-lactam compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease, wherein administration of the medicament to a subject in need thereof over a period of time results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0317] In some aspects, the present disclosure provides a use of a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease, wherein administration of the medicament to a subject in need thereof over a period of time results in a plasma concentration of the β-lactam compound having: administering the β-lactam compound, or a pharmaceutically acceptable salt thereof, and probenecid, or a pharmaceutically acceptable salt thereof, to a subject in need thereof over a period of time, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said β-lactam compound without probenecid over said time period, A higher maximum plasma concentration (C ) in the subject in need thereof, during the time period, compared to the comparable subject administered the pharmaceutically effective amount of the β-lactam compound without probenecid. max ),or Its combination.

[0318] Exemplary Methods In some aspects, the present disclosure provides a method of treating or preventing a disease, the method comprising administering to a subject in need thereof an oral co-formulation of about 500 mg of Compound III-2b and about 500 mg of probenecid, wherein said administration results in a plasma concentration of Compound III-2b having: A higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered Compound III-2b and probenecid by a different route of administration, said area under the curve being about 20% or more higher within about 1 day from said administration; and Substantially the same maximum plasma concentration (C ) in said subject in need thereof compared to comparable subjects administered Compound III-2b and probenecid by a different route of administration. max ).

[0319] In some aspects, the present disclosure provides a method of treating or preventing a disease, the method comprising administering to a subject in need thereof an oral co-formulation of about 500 mg of Compound III-2b and about 500 mg of probenecid, wherein the administration results in an area under the curve (AUC) of the plasma concentration of compound III-2b of about 4800 ng·h / mL to about 4850 ng·h / mL within about 12 hours from the administration, and a maximum plasma concentration (C max ) is about 1800 ng / mL to about 1850 ng / mL.

[0320] In some aspects, the present disclosure provides a method of treating or preventing a disease, the method comprising administering to a subject in need thereof an oral co-formulation of about 500 mg of Compound III-2b and about 500 mg of probenecid, wherein the administration results in an area under the curve (AUC) of the plasma concentration of compound III-2b of about 7550 ng·h / mL to about 8000 ng·h / mL within about 12 hours from the administration, and a maximum plasma concentration (C max ) is about 2650 ng / mL to about 2700 ng / mL.

[0321] Pharmaceutical compositions and pharmaceutical kits In some aspects, the present disclosure provides a pharmaceutical composition comprising a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

[0322] In some embodiments, the pharmaceutical composition is an oral dosage form.

[0323] In some embodiments, the pharmaceutical composition comprises: 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof; and 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg of probenecid or a pharmaceutically acceptable salt thereof.

[0324] In some embodiments, the pharmaceutical composition comprises about 500 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof; and about 500 mg of probenecid or a pharmaceutically acceptable salt thereof.

[0325] In some embodiments, the pharmaceutical composition comprises about 500 mg of Compound III-2b and about 500 mg of probenecid.

[0326] In some embodiments, when administered to a subject in need thereof, the pharmaceutical composition results in one or more effects disclosed herein (e.g., AUC and / or C of the β-lactam compound disclosed herein). max ).

[0327] In some aspects, the present disclosure provides a pharmaceutical kit comprising a β-lactam compound or a pharmaceutically acceptable salt thereof in a first package and probenecid or a pharmaceutically acceptable salt thereof in a second package.

[0328] In some embodiments, at least one of the β-lactam compound or a pharmaceutically acceptable salt thereof or probenecid or a pharmaceutically acceptable salt thereof is in an oral dosage form; Preferably, the β-lactam compound or a pharmaceutically acceptable salt thereof is in an oral dosage form, or probenecid or a pharmaceutically acceptable salt thereof is in an oral dosage form; More preferably, the β-lactam compound or a pharmaceutically acceptable salt thereof or probenecid or a pharmaceutically acceptable salt thereof are both in oral dosage form.

[0329] In some embodiments, when used by a subject in need thereof, the pharmaceutical kit results in one or more effects disclosed herein (e.g., AUC and / or C of the β-lactam compound disclosed herein). max ).

[0330] In some embodiments, the pharmaceutical kit comprises: 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof in a first package; and 20 mg to about 5 g, about 50 mg to about 2 g, about 80 mg to about 1 g, about 100 mg to about 900 mg, about 200 mg to about 800 mg, about 300 mg to about 700 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, or about 480 mg to about 520 mg of probenecid or a pharmaceutically acceptable salt thereof in a second package.

[0331] In some embodiments, the pharmaceutical composition comprises about 500 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof in a first package; and about 500 mg of probenecid or a pharmaceutically acceptable salt thereof in a second package.

[0332] In some embodiments, the pharmaceutical composition comprises about 500 mg of Compound III-2b in a first package and about 500 mg of probenecid in a second package.

[0333] Other suitable compounds In some aspects, the present disclosure provides a compound or a pharmaceutical salt thereof, wherein administration of the compound or a pharmaceutical salt thereof in combination with probenecid or a pharmaceutically acceptable salt thereof by the same route of administration in a subject in need thereof results in a plasma concentration versus time profile of the compound having: a higher area under the curve (AUC) in the subject in need thereof compared to comparable subjects administered the compound and probenecid by a different route of administration; Substantially the same maximum plasma concentration (C ) in the subject in need thereof compared to comparable subjects administered the compound and probenecid by a different route of administration. max );or Its combination.

[0334] In some aspects, the present disclosure provides a compound or a pharmaceutical salt thereof, wherein administration of the compound or a pharmaceutical salt thereof in combination with probenecid or a pharmaceutically acceptable salt thereof in a subject in need thereof over a period of time results in a plasma concentration versus time profile of the compound having: a higher area under the curve (AUC) in said subject in need thereof compared to a comparable subject administered with said pharmaceutically effective amount of said compound without administration of probenecid over said time period, A higher maximum plasma concentration (C ) of the compound in the subject in need thereof during the time period as compared to the comparable subject administered the pharmaceutically effective amount of the compound without probenecid. max ),or Its combination.

[0335] In some embodiments, the compound is selected from: Latanoprost acid PGH2 PGE1 PGE2 PGF 2α Thromboxane B2 Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0336] In some embodiments, the compound is selected from: Aliskiren Atorvastatin penicillin BDE47 BDE99 BDE153 Bosentan Sodium tetrabromophenolphthalein sulfonate CP-671,305 Dehydroepiandrosterone-3-sulfate Eltrombopag Estrone-3-sulfate Ezetimibe glucuronide Fexofenadine Flutavatin Glyburide Latanoprost acid M17055 Mesalazine Montelukast Pravastatin pitavastatin Pregnenolone Sulfate PGE2 Rosuvastatin Talinolol Taurocholate Tibipenem-Pivoxil Thyroxine (T4) Unoprostone metabolites Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0337] In some embodiments, the compound is selected from: Acebutolol APD-ajmalinium Atenolol Atrasentan Bamet-R2 Bamet-UD2 Bilirubin BQ-123 Sodium tetrabromophenolphthalein sulfonate Celiprol Chlorambucil-taurocholate Taurocholate Ciprofloxacin CRC220 Darunavir Dehydroepiandrosterone-3-sulfate Deltorphin II [D-Penicillamine 2.5 Enkephalin Enoxacin Epicatechin Gallate Epigallocatechin Gallate Erythromycin Estradiol-17β-glucuronide Estrone-3-sulfate Fexofenadine Gatifloxacin Gd-B20790 Glycocholate Hydroxyurea Imatinib Labetalol Levofloxacin Lomefloxacin Lopinavir Methotrexate Microcystin N-Methylquinidine N-Methylquinine Nadolol Norfloxacin Strophanthin G pitavastatin PGE2 Reverse triiodothyronine (rT3) Rocuronium Rosuvastatin Saquinavir Sotalol Talinolol Taurocholate Taurochenodeoxycholate Tauroursodeoxycholate Thyroxine (T4) Tibipenem-Pivoxil TR-14035 Triiodothyronine (T3) Unoprostone metabolites Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0338] In some embodiments, the compound is monobactam.

[0339] In some embodiments, the compound is aztreonam, tigemonam, carumonam, nocardin A, an analog thereof, or a derivative thereof.

[0340] In some embodiments, the compound is a penicillem, carbapenem, or clavulane.

[0341] In some embodiments, the compound is penicillin, benzathine penicillin, procaine penicillin, penicillin V, propicillin, pheneticillin, azidocillin, clomethicillin, penacillin, cloxacillin (e.g., dicloxacillin or flucloxacillin), oxacillin, nafcillin, methicillin, amoxicillin, ampicillin (e.g., pivampicillin, hetacillin, bacampicillin, metamcillin, talampicillin), epicillin, ticarcillin, carbenicillin, carbocillin, temocillin, piperacillin, azlocillin, mezlocillin, mecillin (e.g., pivampicillin), sulbenicillin, a pharmaceutically acceptable salt thereof, a prodrug thereof, an analog thereof, or a derivative thereof.

[0342] In some embodiments, the compound is a penem or a carbapenem.

[0343] In some embodiments, the compound is thiopenem, oxypenem, aminopenem, alkylpenem, or arylpenem.

[0344] In some embodiments, the compound is ertapenem, anti-Pseudomonas aeruginosa (eg, doripenem, imipenem, meropenem), biapenem, panipenem, sulopenem, a pharmaceutically acceptable salt thereof, a prodrug thereof, an analog thereof, or a derivative thereof.

[0345] In some embodiments, the compound is a cephem, a carbacephem, or an oxacephem.

[0346] In some embodiments, the compound is cefazolin, cephalexin, cefadroxil, cefpirin, cefazedone, cefazolidinone, cephradine, cefuroxime, cefotaxime, cefotaxime, ceftriaxone, cefaclor, cefotetan, cephalosporins (e.g., cefxitin, cefprozil, cefuroxime, cefuroxime acetoxyethyl, cefmandole, cefminox, cefonicid, cefoperazone, cefotaxime, cefotaxime, cefotiam, cefuroxime, cefotax ... Carbacephems (e.g. loracarb), cefixime, ceftriaxone, anti-Pseudomonas aeruginosa (e.g. ceftazidime, cefoperazone), cefdinir, cefcaprine, cefdoxime, ceftizoxime, cefmenoxime, ceftriaxone, cefpiramide, cefpodoxime, ceftibuten, cefditoren, cefetamet, cefdizime, cefimizolin, cefsulodin, cefditoren, ceftiolin, oxacephems (e.g. flumoxef, latamoxef), cefepime, cefazolin, cefpirome, ceftriaxone, ceftaroline fosamil, ceftolozane, ceftobiprole, ceftiofur, cefquinome, cefvectin, pharmaceutically acceptable salts thereof, prodrugs thereof, analogs thereof or derivatives thereof.

[0347] In some embodiments, the compound is thiopenem.

[0348] In some embodiments, the compound has formula (I): Its pharmaceutically acceptable salt, prodrug, analog or derivative thereof, wherein R 1 is H or optionally substituted alkyl.

[0349] In some embodiments, the compound has Formula (Ia): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0350] In some embodiments, the compound has Formula (Ib): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0351] In some embodiments, R 1 For H.

[0352] In some embodiments, the compound has formula (II): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0353] In some embodiments, the compound has formula (IIa): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0354] In some embodiments, the compound has formula (IIb): A pharmaceutically acceptable salt, a prodrug, an analog or a derivative thereof.

[0355] In some embodiments, R 1 is an optionally substituted alkyl group.

[0356] In some embodiments, the compound has any one of formula (III), (IIIa), and (IIIb): Its pharmaceutically acceptable salt, prodrug, analog or derivative thereof, wherein R 2 is H or optionally substituted alkyl.

[0357] In some embodiments, the compound is selected from: Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0358] In some embodiments, the compound is selected from: Its pharmaceutically acceptable salts, prodrugs, analogs and derivatives.

[0359] In some embodiments, the compound has any one of Formula (IV), (IVa), and (IVb): Its pharmaceutically acceptable salt, prodrug, analog or derivative thereof, wherein R 3 is H or optionally substituted alkyl.

[0360] In some embodiments, R 3 It is a C2-C8 alkyl group.

[0361] In some embodiments, R 3 It is CH2CH3, CH2CH2CH3 or CH2CH(CH3)2.

[0362] definition As used herein, "alkyl", "C1, C2, C3, C4, C5 or C6 alkyl" or "C1-C6 alkyl" is intended to include C1, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or C6 branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include C1, C2, C3, C4, C5 and C6 alkyl groups. Examples of alkyl groups include moieties having 1-6 carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl or n-hexyl. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms (e.g., C1-C6 for a straight chain and C3-C6 for a branched chain), and in another embodiment, a straight chain or branched chain alkyl has 4 or fewer carbon atoms.

[0363] As used herein, the term "cycloalkyl" refers to a cycloalkyl group having 3 to 30 carbon atoms (e.g., C3-C 12 、C3-C 10 The saturated or unsaturated non-aromatic hydrocarbon monocyclic or polycyclic (e.g., fused, bridged or spiro) system of C3-C8 (C3-C8). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthyl and adamantyl.

[0364] Unless otherwise indicated, the term "heterocycloalkyl" as used herein refers to a saturated or unsaturated non-aromatic 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged or spiro) or 11-14 membered tricyclic ring system (fused, bridged or spiro) having one or more heteroatoms (e.g., O, N, S, P or Se), such as 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or such as 1, 2, 3, 4, 5 or 6 heteroatoms independently selected from nitrogen, oxygen and sulfur. Examples of heterocycloalkyl include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolyl, indolyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxirane, azetidinyl, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl , 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 1,4-dioxa-8-azaspiro[4.5]decyl, 1,4-dioxaspiro[4.5]decyl, 1-oxaspiro[4.5]decyl, 1-azaspiro[4.5]decyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl, 7'H-spiro[cyclohexane-1,5'-furo[3,4-b]pyridinyl]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridinyl]-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexan-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazol[3 ,4-c]pyridinyl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptyl, 2-methyl-2-azaspiro[3.3]heptyl, 2-azaspiro[3.5]nonanyl, 2-methyl-2-azaspiro[3.5]nonanyl, 2-azaspiro[4.5]decanyl, 2-methyl-2-azaspiro[4.5]decanyl, 2-oxa-azaspiro[3.4]octan-6-yl, 2-oxa-azaspiro[3.4]octan-6-yl, etc. In the case of polycyclic non-aromatic rings, only one ring needs to be non-aromatic (e.g., 1,2,3,4-tetrahydronaphthyl or 2,3-dihydroindole).

[0365] As used herein, the term "optionally substituted alkyl" refers to unsubstituted alkyl groups or alkyl groups having specified substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, aminosulfonyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0366] As used herein, term " alkenyl " includes unsaturated aliphatic groups, and its length and possible substitution are similar to the above-mentioned alkyl, but contain at least one double bond.For example, term " alkenyl " includes straight chain alkenyl (for example, vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl) and branched alkenyl.In certain embodiments, straight chain or branched alkenyl has 6 or less carbon atoms (for example, C2-C6 for straight chain, C3-C6 for branched chain) in its main chain.Term " C2-C6 " includes alkenyl containing 2-6 carbon atoms.Term " C3-C6 " includes alkenyl containing 3-6 carbon atoms.

[0367] As used herein, term "alkynyl" includes unsaturated aliphatic groups, and its length and possible substitution are similar to the above-mentioned alkyl, but it contains at least one triple bond. For example, "alkynyl" includes straight chain alkynyl (for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl) and branched chain alkynyl. In certain embodiments, straight chain or branched chain alkynyl has 6 or less carbon atoms (for example, C2-C6 for straight chain, C3-C6 for branched chain) in its main chain. The term "C2-C6" includes alkynyl containing 2-6 carbon atoms. The term "C3-C6" includes alkynyl containing 3-6 carbon atoms. As used herein, "C2-C6 alkenylene linking group" or "C2-C6 alkynylene linking group" is intended to include C2, C3, C4, C5 or C6 chain (linear or branched) divalent unsaturated aliphatic hydrocarbon groups. For example, a C2-C6 alkenylene linker is intended to include C2, C3, C4, C5, and C6 alkenylene linkers.

[0368] Other optionally substituted parts (e.g., optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl) include both unsubstituted parts and parts with one or more specified substituents. For example, substituted heterocycloalkyl includes those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.

[0369] As used herein, the term "aryl" includes groups having aromatic properties, including "conjugated" or polycyclic ring systems having one or more aromatic rings and not containing any heteroatoms in the ring structure. Examples include phenyl, naphthyl, and the like.

[0370] As used herein, the term "heteroaryl" is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic aromatic heterocycle consisting of carbon atoms and one or more heteroatoms, such as 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or such as 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from nitrogen, oxygen, and sulfur. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as defined). The nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., N→O and S(O)). p , wherein p=1 or 2). Note that the total number of S and O atoms in the aromatic heterocyclic ring does not exceed 1. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.

[0371] In addition, the terms "aryl" and "heteroaryl" include polycyclic aromatic and heteroaryl groups, for example, tricyclic, bicyclic, for example, naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.

[0372] The cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings may be substituted at one or more ring positions (e.g., a ring carbon or heteroatom such as N) with substituents as described above, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, amino The aryl and heteroaryl groups may also be fused or bridged with alicyclic or heterocyclic rings that are not aromatic to form a polycyclic system (e.g., tetralin, methylenedioxyphenyl such as benzo[d][1,3]dioxol-5-yl).

[0373] As used herein, the term "carbocycle" or "carbocyclic ring" is intended to include any stable monocyclic, bicyclic, or tricyclic ring having the specified number of carbon atoms, any one of which may be saturated, unsaturated, or aromatic. Carbocycles include cycloalkyl and aryl. For example, C3-C 14 Carbocycle is intended to include monocycles, bicyclics or tricyclics with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms. Examples of carbocycle include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl, naphthyl, indanyl, adamantyl and tetrahydronaphthyl. Bridged rings are also included in the definition of carbocycle, including, for example, [3.3.0] bicyclooctane, [4.3.0] bicyclononane, [4.4.0] bicyclodecane and [2.2.2] bicyclooctane. When one or more carbon atoms connect two non-adjacent carbon atoms, bridged rings occur. In one embodiment, bridged rings are one or two carbon atoms. Note that bridges always convert monocycles into tricyclics. When a ring is bridged, substituents recited for the ring may also be present on the bridge. Also included are fused rings (eg, naphthyl, tetrahydronaphthyl) and spiro rings.

[0374] As used herein, the term "heterocycle" or "heterocyclyl" includes any ring structure (saturated, unsaturated or aromatic) containing at least one ring heteroatom (e.g., 1-4 heteroatoms selected from N, O and S). Heterocycles include heterocycloalkyl and heteroaryl. Examples of heterocycles include, but are not limited to, morpholine, pyrrolidine, tetrahydrothiophene, piperidine, piperazine, oxetane, pyran, tetrahydropyran, azetidine and tetrahydrofuran.

[0375] Examples of heterocyclic groups include, but are not limited to, acridinyl, azacyclooctenyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, dihydropyranyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolyl, indolizinyl, indolyl, 3H-indolyl, isatoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl (e.g., benzo[d][1,3]dioxol-5-yl), morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazol-5(4H)-one, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, Quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, phenylthio, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.

[0376] As used herein, the term "substituted" refers to any one or more hydrogen atoms on a designated atom being replaced by a group selected from the indicated group, provided that the normal valence of the designated atom is not exceeded and the substitution results in a stable compound. When the substituent is an oxo or keto group (i.e., =O), then 2 hydrogen atoms on the atom are replaced. There is no keto substituent on the aromatic moiety. As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N or N=N). "Stable compound" and "stable structure" are intended to indicate a compound that is robust enough to withstand separation from a reaction mixture to a useful purity and formulated into an effective therapeutic agent.

[0377] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is listed without indicating the atom through which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded to any atom in the formula. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0378] When any variable (e.g., R) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R moieties, then that group may be optionally substituted with up to two R moieties, and R at each occurrence is independently selected from the definition of R. Additionally, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0379] As used herein, the term "hydroxy" or "hydroxyl" includes a group having -OH or -O - The group.

[0380] As used herein, the term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine. The term "perhalogenated" generally refers to a moiety in which all hydrogen atoms are replaced by halogen atoms. The term "haloalkyl" or "haloalkoxy" refers to an alkyl or alkoxy group substituted with one or more halogen atoms.

[0381] The term "carbonyl" as used herein includes compounds and moieties containing a carbon connected to an oxygen atom by a double bond. Examples of carbonyl containing moieties include, but are not limited to, aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, and the like.

[0382] The term "carboxyl" as used herein refers to -COOH or a C1-C6 alkyl ester thereof.

[0383] As used herein, the term "acyl" includes moieties containing an acyl group (RC(O)-) or a carbonyl group. As used herein, the term "substituted acyl" includes acyl groups in which one or more hydrogen atoms are replaced by, for example, alkyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, aminosulfonyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0384] As used herein, the term "alkoxy" or "alkoxyl" includes substituted and unsubstituted alkyl, alkenyl and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy or alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropoxy, propoxy, butoxy and pentoxy. Examples of substituted alkoxy groups include haloalkoxy. The alkoxy group can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, aminosulfonyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Examples of halogen-substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy.

[0385] As used herein, the term "ether" or "alkoxy" includes compounds or moieties containing an oxygen bonded to two carbon atoms or heteroatoms. For example, the term includes "alkoxyalkyl," which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom that is covalently bonded to an alkyl group.

[0386] As used herein, the term "ester" includes compounds or moieties containing a carbon or heteroatom bonded to an oxygen atom bonded to the carbon of a carbonyl group. The term "ester" includes alkoxycarboxyl groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, and the like.

[0387] As used herein, the term "thioalkyl" includes compounds or moieties containing an alkyl group connected to a sulfur atom.Thioalkyl can be substituted by a group such as an alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxylic acid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and urea), amidino, imino, sulfydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, aminosulfonyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclic radical, alkylaryl or aromatic or heteroaromatic moiety.

[0388]

[00136] The term "thiocarbonyl" or "thiocarboxy" as used herein includes compounds and moieties containing a carbon double bonded to a sulfur atom.

[0389] As used herein, the term "thioether" includes a portion containing a sulfur atom bonded to two carbon atoms or heteroatoms. Examples of thioethers include, but are not limited to, alkylthioalkyl, alkylthioalkenyl, and alkylthioalkynyl. The term "alkylthioalkyl" includes a portion having an alkyl, alkenyl, or alkynyl bonded to a sulfur atom, the sulfur atom being bonded to the alkyl. Similarly, the term "alkylthioalkenyl" refers to a portion in which an alkyl, alkenyl, or alkynyl is bonded to a sulfur atom, the sulfur atom being covalently bonded to the alkenyl; "alkylthioalkynyl" refers to a portion in which an alkyl, alkenyl, or alkynyl is bonded to a sulfur atom, the sulfur atom being covalently bonded to the alkynyl.

[0390] As used herein, the term "amine" or "amino" refers to -NH2. "Alkylamino" includes groups of compounds in which the nitrogen of -NH2 is bonded to at least one alkyl group. Examples of alkylamino include benzylamino, methylamino, ethylamino, phenethylamino, and the like.

[0391] As used herein, the term "dialkylamino" includes groups in which the nitrogen of -NH2 is bonded to two alkyl groups. Examples of dialkylamino groups include, but are not limited to, dimethylamino and diethylamino.

[0392] The terms "arylamino" and "diarylamino" as used herein include groups wherein the nitrogen is bonded to at least one or two aryl groups, respectively.

[0393] As used herein, the terms "aminoaryl" and "aminoaryloxy" refer to aryl and aryloxy groups substituted with an amino group.

[0394] The term "alkylarylamino," "alkylaminoaryl," or "arylaminoalkyl," as used herein, refers to an amino group bonded to at least one alkyl group and at least one aryl group.

[0395] The term "alkylaminoalkyl" as used herein refers to an alkyl, alkenyl, or alkynyl group bonded to a nitrogen atom which is also bonded to an alkyl group.

[0396] As used herein, the term "acylamino" includes groups in which the nitrogen is bonded to an acyl group. Examples of acylamino groups include, but are not limited to, alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido.

[0397]

[0063] The term "amide" or "aminocarboxy" as used herein includes compounds or moieties containing a nitrogen atom bonded to the carbon of a carbonyl or thiocarbonyl group.

[0398] The term "alkylaminocarboxy" as used herein includes an alkyl, alkenyl or alkynyl group bonded to an amino group which is bonded to the carbon of a carbonyl or thiocarbonyl group.

[0399] The term "arylaminocarboxy" as used herein includes aryl or heteroaryl moieties bonded to an amino group which is bonded to the carbon of a carbonyl or thiocarbonyl group.

[0400] The terms "alkylaminocarboxy," "alkenylaminocarboxy," "alkynylaminocarboxy," and "arylaminocarboxy," as used herein, include moieties in which the alkyl, alkenyl, alkynyl, and aryl moieties, respectively, are bonded to a nitrogen atom which, in turn, is bonded to the carbon of a carbonyl group.

[0401] The amide may be substituted with substituents such as straight chain alkyl, branched chain alkyl, cycloalkyl, aryl, heteroaryl or heterocycle. The substituents on the amide group may be further substituted.

[0402] It will be appreciated that probenecid (eg, sold under the trade name Probalan) has the following structure:

[0403] Compounds of the present disclosure that contain nitrogen can be converted to N-oxides by treatment with an oxidizing agent (e.g., 3-chloroperoxybenzoic acid (mCPBA) and / or hydrogen peroxide) to provide other compounds of the present disclosure. Thus, when valence and structure permit, all shown and claimed nitrogen-containing compounds are considered to include the shown compounds and their N-oxide derivatives (which may be designated as N→O or N + -O -) both. In addition, in other cases, the nitrogen in the compounds of the present disclosure can be converted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds can be prepared by oxidizing the parent amine with an oxidant (such as m-CPBA). When valence and structure permit, all nitrogen-containing compounds shown and claimed are also considered to cover both the compounds shown and their N-hydroxy (i.e., N-OH) and N-alkoxy (i.e., N-OR, wherein R is a substituted or unsubstituted C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, 3-14-membered carbocyclic ring or 3-14-membered heterocyclic ring) derivatives.

[0404] In this specification, for convenience, in some cases, the structural formula of the compound represents certain isomers, but the present disclosure includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, etc., and it should be understood that not all isomers can have the same level of activity. In addition, for the compound represented by the chemical formula, there may be crystalline polymorphs. It should be noted that any crystalline form, crystalline form mixture or its anhydride or hydrate is included in the scope of the present disclosure.

[0405] The term "isomers" as used herein refers to compounds that have the same molecular formula but differ in the sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers", while stereoisomers that are non-superimposable mirror images of one another are termed "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture".

[0406] As used herein, the term "chiral center" refers to a carbon atom to which are bonded four different substituents.

[0407] As used herein, the term "chiral isomer" refers to a compound having at least one chiral center. Compounds having more than one chiral center may exist as individual diastereomers or a mixture of diastereomers (called a "diastereomeric mixture"). When there is one chiral center, the stereoisomers may be characterized by the absolute configuration (R or S) of the chiral center. The absolute configuration refers to the spatial arrangement of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are according to the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).

[0408] The term "geometric isomers" as used herein refers to the existence of diastereomers due to hindered rotation around double bonds or cycloalkyl linkers (e.g., 1,3-cyclobutyl). These configurations are distinguished in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite sides of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

[0409] It should be understood that the compounds of the present disclosure may be described as different chiral isomers or geometric isomers. It should also be understood that when a compound has chiral isomers or geometric isomers, all isomeric forms are intended to be included within the scope of the present disclosure, and the naming of the compound does not exclude any isomeric form, and it should be understood that not all isomers may have the same level of activity.

[0410] It should be understood that the structures and other compounds discussed in this disclosure include all atropic isomers thereof. It should also be understood that not all atropic isomers may have the same level of activity.

[0411] The term "atropisomer" as used herein is a type of stereoisomer in which the atoms of the two isomers are arranged differently in space. Atropisomers exist due to restricted rotation caused by the hindrance of rotation of large groups around a central bond. Such atropisomers usually exist as a mixture, however, due to recent advances in chromatographic techniques, it has become possible to separate mixtures of two atropisomers under selected circumstances.

[0412] As used herein, the term "tautomer" is one of two or more structural isomers that exist in equilibrium and are easily converted from one isomeric form to another. This conversion results in the formal migration of hydrogen atoms, accompanied by the conversion of adjacent conjugated double bonds. Tautomers exist as a mixture of tautomer groups in solution. In a solution where tautomerization is possible, the chemical equilibrium of tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that can be mutually converted by tautomerization is called tautomerism. Among the various types of tautomerism that may be possible, two types are usually observed. In keto-enol tautomerism, the movement of electrons and hydrogen atoms occurs simultaneously. Due to the reaction of the aldehyde group (-CHO) in the sugar chain molecule with a hydroxyl group (-OH) in the same molecule, to obtain the cyclic (ring-shaped) form shown by glucose, ring-chain tautomerism occurs.

[0413] It should be understood that the compounds of the present disclosure can be described as different tautomers. It should also be understood that when a compound has a tautomeric form, all tautomeric forms are intended to be included within the scope of the present disclosure, and the naming of the compound does not exclude any tautomeric form. It will be understood that certain tautomers can have a higher level of activity than other tautomers.

[0414] As used herein, the terms "crystalline polymorph", "polymorph" or "crystal form" refer to crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, crystallization rate, storage temperature and other factors can cause one crystal form to dominate. Crystal polymorphs of a compound can be prepared by crystallization under different conditions.

[0415] It should be understood that the compounds of any formula described herein include the compounds themselves, as well as their salts and their solvates, if applicable. For example, salts can be formed between anions and positively charged groups (e.g., amino groups) on substituted benzene compounds. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, toluenesulfonate, salicylate, lactate, naphthenesulfonate and acetate (e.g., trifluoroacetate).

[0416] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between cations and negatively charged groups (e.g., carboxylates) on substituted benzene compounds. Suitable cations include sodium ions, potassium ions, magnesium ions, calcium ions, and ammonium cations (e.g., tetramethylammonium ions). Substituted benzene compounds also include those salts containing quaternary nitrogen atoms.

[0417] It should be understood that the compounds of the present disclosure (e.g., salts of the compounds) can exist in hydrated or unhydrated (anhydrous) form or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.

[0418] The term "solvate" as used herein refers to an addition form containing a stoichiometric or non-stoichiometric amount of a solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate; and if the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with one molecule of a substance, wherein the water remains in its molecular state as H2O.

[0419] As used herein, the term "analog" refers to a compound that is similar in structure to another compound but slightly different in composition (e.g., one atom is replaced by an atom of a different element or a specific functional group is present, or one functional group is replaced by another functional group). Thus, an analog is a compound that is similar or comparable to a reference compound in function and appearance, but not similar to the reference compound in structure or origin.

[0420] As used herein, the term "derivative" refers to compounds having a common core structure and being substituted with various groups as described herein.

[0421] As used herein, the term "bioisostere" refers to a compound obtained by exchanging one atom or a group of atoms with another broadly similar atom or a group of atoms. The purpose of bioisosteric substitution is to produce new compounds with similar biological properties to the parent compound. Bioisosteric substitution can be based on physicochemistry or topology. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonimides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.

[0422] It should be understood that the present disclosure is intended to include all isotopes of atoms present in the compounds of the present invention. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include tritium and deuterium, while isotopes of carbon include C-13 and C-14.

[0423] Unless otherwise specified, the expressions "one or more of A, B or C", "one or more A, B or C", "one or more of A, B and C", "one or more A, B and C", "selected from A, B and C", "selected from A, B and C", etc. as used herein are used interchangeably and all refer to selected from A, B and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof.

[0424] It is understood that the present disclosure provides methods for synthesizing compounds of any formula described herein. The present disclosure also provides detailed methods for synthesizing various disclosed compounds of the present disclosure according to the following schemes as well as those shown in the examples.

[0425] It should be understood that throughout the specification, when a composition is described as having, including or comprising a particular component, it is contemplated that the composition is also substantially composed of or consists of said component. Similarly, when a method or process is described as having, including or comprising a particular process step, the process is also substantially composed of or consists of said method steps. In addition, it should be understood that the order of steps or the order for performing certain actions is unimportant as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.

[0426] It should be understood that the synthetic methods disclosed herein can tolerate a wide variety of functional groups, and therefore can use various substituted starting materials. The methods generally provide the desired final compound at or near the end of the entire method, but in some cases it may be necessary to further convert the compound into a pharmaceutically acceptable salt thereof.

[0427] It should be understood that the compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art or which will be apparent to those skilled in the art in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or a few sources, classical textbooks are useful and recognized reference textbooks on organic synthesis known to those skilled in the art, such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Edition, John Wiley & Sons: New York, 2001; Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), which are incorporated herein by reference.

[0428] Those of ordinary skill in the art will note that during the reaction sequence and synthesis scheme described herein, the order of some steps can be changed, such as introducing and removing blocking groups. Those of ordinary skill in the art will recognize that some groups may need to be protected from the influence of reaction conditions by using blocking groups. Blocking groups can also be used to distinguish similar functional groups in molecules. Blocking groups and how to introduce and remove the enumeration of these groups can be found in Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons: New York, 1999.

[0429] It should be understood that, unless otherwise indicated, any description of a method of treatment includes using the compound to provide such treatment or prevention as described herein, as well as using the compound to prepare a medicament for treating or preventing such a condition. Treatment includes treating humans or non-human animals, including rodents and other disease models.

[0430] As used herein, the term "subject" is interchangeable with the term "subject in need thereof," and both refer to a subject suffering from a disease or having an increased risk of developing a disease. "Subject" includes mammals. The mammal can be, for example, a human or a suitable non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. The subject can also be a bird or poultry. In one embodiment, the mammal is a human.

[0431] As used herein, the term "comparable subject" refers to a subject with comparable parameters or in comparable conditions, such as a subject being compared (e.g., a subject being treated). For example, a "comparable subject" may have the disease of the subject being compared, or have an increased risk of developing the disease of the subject being compared. For another example, a "comparable subject" may exhibit one or more plasma pharmacokinetic parameters (e.g., C ) of one or more agents (e.g., a β-lactam compound, probenecid, or a combination thereof) that are comparable to those of the subject being compared. max In some embodiments, a "comparable subject" can be a subject being compared at a different time, e.g., a subject being treated (e.g., by administration of a β-lactam compound and probenecid) can be subjected to a condition as a "comparable subject" prior to treatment (e.g., administration of a β-lactam compound without administration of probenecid).

[0432] The term "candidate compound" as used herein refers to a compound of the present disclosure or a pharmaceutically acceptable salt, polymorph or solvate thereof, which has been or will be tested in one or more in vitro or in vivo biological assays to determine whether the compound may cause the desired biological or medical response sought by a researcher or clinician in a cell, tissue, system, animal or human. A candidate compound is a compound of the present disclosure or a pharmaceutically acceptable salt, polymorph or solvate thereof. The biological response or effect may occur in vitro or in an animal model, as well as other biological changes observable in vitro. In vitro or in vivo biological assays may include, but are not limited to, enzyme activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and assays described herein.

[0433] As used herein, the terms "treating" or "treatment" describe the management and care of a patient for the purpose of combating a disease, condition, or disorder, and include the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph, or solvate thereof, to alleviate the symptoms or complications of a disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The term "treatment" may also include treatment of in vitro cells or animal models.

[0434] As used herein, the term "close in time" refers to a therapeutic agent (e.g., a β-lactam compound disclosed herein) that is administered in a time period before or after the administration of another therapeutic agent (e.g., probenecid), so that the therapeutic effect of one therapeutic agent overlaps with the therapeutic effect of another therapeutic agent. In some embodiments, the therapeutic effect of one therapeutic agent completely overlaps with the therapeutic effect of another therapeutic agent. In some embodiments, "close in time" refers to a therapeutic agent that is administered in a time period before or after the administration of another therapeutic agent, so that there is a synergistic effect between one therapeutic agent and another therapeutic agent. "Close in time" can vary according to various factors, including but not limited to the age, sex, weight, genetic background, medical condition, medical history, and treatment history of the subject to whom the therapeutic agent is to be administered; the disease or condition to be treated or improved; the therapeutic outcome to be achieved; the dosage, frequency of administration, and duration of administration of the therapeutic agent; the pharmacokinetics and pharmacodynamics of the therapeutic agent; and one or more routes of administration of the therapeutic agent. In some embodiments, "close in time" means within 15 minutes, within 30 minutes, within 1 hour, within 2 hours, within 4 hours, within 6 hours, within 8 hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 1 week, within 2 weeks, within 3 weeks, within 4 weeks, within 6 weeks, or within 8 weeks. In some embodiments, multiple administrations of one therapeutic agent can occur close in time to a single administration of another therapeutic agent. In some embodiments, close in time can change during a treatment cycle or within a dosing regimen.

[0435] It will be appreciated that the compounds of the present disclosure, or pharmaceutically acceptable salts, polymorphs or solvates thereof, can or may also be used to prevent related diseases, conditions or disorders, or to identify suitable candidates for such purposes.

[0436] The terms "preventing," "prevent," or "protection" as used herein describe reducing or eliminating the onset of symptoms or complications of such a disease, condition, or disorder.

[0437] It should be understood that those skilled in the art can refer to general reference textbooks to describe in detail the known techniques or equivalent techniques discussed herein. These textbooks include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd Edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2000); Coligan et al., Current Protocols in Immunology, John Wiley & Sons, NY; Enna et al., Current Protocols in Pharmacology, John Wiley & Sons, NY; Fingl et al., The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 18th Edition (1990), Mandell et al., Principles and Practice of Infectious Diseases, Saunders Publishing (8th Edition, 2014). Of course, these textbooks can also be referenced when making or using an aspect of the present disclosure.

[0438] As used herein, the term "combination therapy" or "co-therapy" includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph, or solvate thereof, and at least a second agent as part of a specific treatment regimen that is intended to provide a beneficial effect from the co-action of these therapeutic agents. The beneficial effects of the combination include, but are not limited to, pharmacokinetic or pharmacodynamic co-actions resulting from the combination of therapeutic agents.

[0439] It will be understood that the present disclosure also provides pharmaceutical compositions comprising any of the compounds described herein in combination with at least one pharmaceutically acceptable excipient or carrier.

[0440] The term "pharmaceutical composition" as used herein is a preparation containing a compound of the present disclosure, which is in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a single pump or vial on a capsule, IV bag, tablet, aerosol inhaler. The amount of active ingredient (e.g., a preparation of a disclosed compound or its salt, hydrate, solvate or isomer) in a unit dose composition is an effective amount and varies according to the specific treatment involved. It will be appreciated by those skilled in the art that it is sometimes necessary to routinely change the dosage according to the age and condition of the patient. The dosage will also depend on the route of administration. It is expected that a variety of routes, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal, etc., are used for topical or transdermal administration of compounds of the present disclosure. Dosage forms include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.

[0441] As used herein, the term "pharmaceutically acceptable" refers to those compounds, anions, cations, materials, compositions, carriers and / or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0442] As used herein, the term "pharmaceutically acceptable excipient" refers to an excipient that can be used to prepare a pharmaceutical composition, which is generally safe, non-toxic, and not biologically or otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. "Pharmaceutically acceptable excipient" as used in the specification and claims includes both one and more than one such excipient.

[0443] It should be understood that the pharmaceutical composition of the present disclosure is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral administration, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous administration may include the following components: sterile diluents, such as water for injection, saline solutions, non-volatile oils, polyethylene glycols, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates, or phosphates; and agents for adjusting tension, such as sodium chloride or glucose. pH can be adjusted with an acid or base (such as hydrochloric acid or sodium hydroxide). Parenteral preparations may be encapsulated in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.

[0444] It should be understood that the compounds or pharmaceutical compositions of the present disclosure can be administered to subjects in many well-known methods currently used for chemotherapy. For example, the compounds of the present disclosure can be injected into the bloodstream or body cavity or orally or applied through the skin with a patch. The selected dose should be sufficient to constitute an effective treatment, but not so high as to cause unacceptable side effects. Preferably, the patient's disease condition and health status are closely monitored during and after treatment for a reasonable period of time.

[0445] As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that treats, ameliorates or prevents a determined disease or condition, or exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician.

[0446] It will be appreciated that for any compound, the therapeutically effective amount can be estimated initially in cell culture assays (e.g., cell culture assays of tumor cells) or in animal models (usually rats, mice, rabbits, dogs, or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for human administration. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell culture or experimental animals, e.g., ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose that is lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as LD 50 / ED 50The dosage may vary within this range depending on the dosage form employed, the sensitivity of the patient, and the route of administration.

[0447] Dosage and administration are adjusted to provide sufficient levels of one or more active agents or to maintain the desired effect. Factors that may be considered include the severity of the disease state, the general health of the subject, the age, weight and sex of the subject, diet, the time and frequency of administration, one or more drug combinations, reaction sensitivity and tolerance / response to treatment. Long-acting pharmaceutical compositions may be administered once every 3-4 days, weekly or biweekly, depending on the half-life and clearance rate of the particular formulation.

[0448] Pharmaceutical compositions containing the active compounds of the present disclosure can be manufactured in a generally known manner, for example by conventional mixing, dissolving, granulating, sugar coating, grinding, emulsifying, encapsulating, embedding or lyophilizing methods. Pharmaceutical compositions can be prepared in a conventional manner using one or more pharmaceutically acceptable carriers, which contain excipients and / or adjuvants that facilitate processing of the active compounds into pharmaceutically useful preparations. Of course, appropriate preparations depend on the selected route of administration.

[0449] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that there is easy injection. It must be stable under manufacturing and storage conditions and must be preserved to prevent the contamination of microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. For example, by using a coating (such as lecithin), by maintaining the required particle size in the case of a dispersion, and by using a surfactant, appropriate fluidity can be maintained. The effect of preventing microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols (such as mannitol and sorbitol) and sodium chloride. The extended absorption of the injectable composition can be achieved by including an agent (such as aluminum monostearate and gelatin) that delays absorption in the composition.

[0450] Sterile injectable solutions can be prepared by incorporating the active compound in the desired amount into an appropriate solvent together with one or a combination of ingredients listed above, followed by sterilization by filtration as required. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation methods are vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional required ingredients from a previously sterile filtered solution thereof.

[0451] Oral compositions typically include an inert diluent or an edible pharmaceutically acceptable carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be blended with an excipient and used in the form of tablets, lozenges or capsules. Oral compositions can also be prepared using a fluid carrier and used as a mouthwash, wherein the compound in the fluid carrier is orally administered, gargled, and spit out or swallowed. Pharmaceutically compatible binders and / or adjuvant materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. can contain any of the following ingredients or compounds of similar nature: binders, such as microcrystalline cellulose, tragacanth or gelatin; excipients, such as starch or lactose; disintegrants, such as alginic acid, Primogel or corn starch; lubricants, such as magnesium stearate or Sterotes; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavorings, such as mint, methyl salicylate or orange flavoring.

[0452] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.

[0453] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be accomplished by the use of nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gel or cream commonly known in the art.

[0454] The active compound can be prepared with a pharmaceutically acceptable carrier that will protect the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. The method for preparing such a preparation is obvious to those skilled in the art. The material can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to cells infected with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0455] It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unit dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. The specifications for the dosage unit forms of the present disclosure are determined by and directly depend on the unique characteristics of the active compound and the specific therapeutic effect to be achieved.

[0456] In therapeutic applications, the dosage of the pharmaceutical composition used according to the present disclosure varies according to the agent, the age, weight and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the treatment, as well as other factors that affect the selected dosage. Generally, the dosage should be sufficient to cause the symptoms of the disease to slow down, and preferably to cause the symptoms of the disease to subside, and also preferably to cause the disease to subside completely. The dosage can be in the range of about 0.01 mg / kg to about 5000 mg / kg per day. In a preferred aspect, the dosage can be in the range of about 1 mg / kg to about 1000 mg / kg per day. In one aspect, the dosage will be in the range of about 0.1 mg / day to about 50 g / day; about 0.1 mg / day to about 25 g / day; about 0.1 mg / day to about 10 g / day; about 0.1 mg to about 3 g / day; or about 0.1 mg to about 1 g / day, in a single dose, divided dose or continuous dose (the dosage can be based on the patient's weight in kg, in m 2 The effective amount of an agent is an amount that provides an objectively discernible improvement as noted by a clinician or other qualified observer. Improvements in survival and growth are indicative of regression. As used herein, the term "dosage effective manner" refers to the amount of active compound that produces a desired biological effect in a subject or cell.

[0457] It will be understood that the pharmaceutical compositions may be included in a container, pack, or dispenser together with instructions for administration.

[0458] It is to be understood that for compounds of the present disclosure that are capable of further forming salts, all such forms are also contemplated to be within the scope of the claimed disclosure.

[0459] The term "pharmaceutically acceptable salt" as used herein refers to a derivative of a compound of the present disclosure, wherein the parent compound is modified by preparing its acid or base salt. In some embodiments, a pharmaceutically acceptable salt of a compound (e.g., a β-lactam compound or probenecid as described herein) is also a prodrug of the compound. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues (e.g., amines), alkali or organic salts of acidic residues (e.g., carboxylates), and the like. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of the parent compound formed by non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonic acid, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, oxaloyl arsenic acid, hexylresorcinic acid, hepatocarboxylic acid, hydrobromic acid, hydrochloric acid, , hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, lactobionic acid, lauryl sulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, naphthalenesulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, aminosulfonic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid and commonly present amino acids (e.g., glycine, alanine, phenylalanine, arginine), etc.

[0460] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, muconic acid, and the like. The present disclosure also includes salts formed when the acidic protons present in the parent compound are replaced by metal ions (e.g., alkali metal ions, alkaline earth metal ions, or aluminum ions); or coordinated with organic bases (e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like). It should be understood that the ratio of the compound to the cation or anion of the salt in the salt form can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3.

[0461] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystalline forms (polymorphs) as defined herein, of the same salt.

[0462] As used herein, the term "prodrug" refers to any agent that is converted in whole or in part into a targeted compound (e.g., a β-lactam compound or probenecid as described herein) when administered to a mammal. In some embodiments, a prodrug of a compound (e.g., a β-lactam compound or probenecid as described herein) is also a pharmaceutically acceptable salt of the compound.

[0463] It should be understood that the compounds of the present disclosure can also be prepared into esters, such as pharmaceutically acceptable esters. For example, the carboxylic acid functional group in the compound can be converted into its corresponding ester, such as methyl ester, ethyl ester or other ester. In addition, the alcohol group in the compound can be converted into its corresponding ester, such as acetate, propionate or other ester.

[0464] The compound or its pharmaceutically acceptable salt is administered orally, nasally, transdermally, pulmonary, inhaled, buccal, sublingual, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectal, intrapleurally, intrathecally and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.

[0465] The dosage regimen utilizing the compound is selected based on a variety of factors, including the type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the patient's renal and liver function; and the specific compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

[0466] Techniques for preparing and administering the disclosed compounds of the present disclosure can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995). In an embodiment, the compounds described herein and pharmaceutically acceptable salts thereof are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical preparation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compound is present in such a pharmaceutical composition in an amount sufficient to provide the desired dosage within the range described herein.

[0467] Unless otherwise stated, all percentages and ratios used herein are by weight. Other features and advantages of the present disclosure are apparent from the various examples. The examples provided illustrate the different components and methods that can be used to practice the present disclosure. These examples do not limit the disclosure claimed. Based on the present disclosure, the skilled person can identify and adopt other components and methods that can be used to practice the present disclosure.

[0468] In the synthetic schemes described herein, for simplicity, compounds may be depicted in one particular configuration. Such a particular configuration should not be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer, or stereoisomer, nor excluding mixtures of isomers, tautomers, regioisomers, or stereoisomers; however, it should be understood that a given isomer, tautomer, regioisomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, regioisomer, or stereoisomer.

[0469] Once the compounds designed, selected and / or optimized by the above methods are generated, they can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, molecules can be characterized by conventional assays, including but not limited to those described below, to determine whether they have the predicted activity, binding activity and / or binding specificity.

[0470] In addition, high throughput screening can be used to accelerate the analysis using such assays. As a result, the activity of the molecules described herein can be quickly screened using techniques known in the art. General methods for performing high throughput screening are described in, for example, Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263. High throughput assays can use one or more different assay techniques, including but not limited to those described below.

[0471] All publications and patent documents cited herein are incorporated herein by reference, just as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. The citation of publications and patent documents is not intended to be an admission that any publication and patent document is relevant prior art, nor does it constitute any admission of its content or date. Now that the invention has been described by written description, those skilled in the art will recognize that the invention can be practiced in various embodiments, and the foregoing description and the following examples are intended to illustrate rather than limit the purpose of the appended claims. Example

[0472] Example 1: Evaluation of the effect of probenecid on plasma pharmacokinetic parameters of β-lactam compounds.

[0473] The effect of probenecid on the pharmacokinetics of sulopneme and its prodrugs (Compound III-2b and Compound III-1b) was studied in a randomized, double-blind (investigator and subject blinded, sponsor disclosed), placebo-controlled, multiple-dose study with or without co-administration of probenecid in the fed or fasted state. 192 subjects were randomly assigned to treatment groups to receive active drug or placebo in the fed or fasted state with or without co-administration of 500 mg probenecid.

[0474] Subjects were dosed twice daily (once every 12 hours) for 6 days, and were dosed once on the 7th day. All treatment groups can be run in parallel or sequentially. Subjects were assigned based on the randomization list. When subjects entered the study group, randomization numbers were assigned sequentially based on the order in which they entered the study. Subjects who withdrew due to reasons unrelated to safety may have been replaced. Blood samples were obtained at predetermined intervals to characterize pharmacokinetics. The results of the study are provided in Tables 1-3.

[0475] Table 1. Plasma pharmacokinetic parameters—fasting conditions (pharmacokinetic population).

[0476] 1 Only day 7 is shown.

[0477] T max Reported as median (min-max).

[0478] AUC inf = Area under the concentration-time curve extrapolated to infinity; AUC last = AUC from time 0 to the last (day 1) quantifiable concentration; AUC tau = area under the concentration-time curve from time 0 to 12 hours; %CV = coefficient of variation; C max = maximum observed concentration; SD = standard deviation; t 1 / 2 = terminal half-life; T max = time to reach maximum observed concentration Table 2. Plasma pharmacokinetic parameters—fed conditions (pharmacokinetic population).

[0479] 1 Only day 7 is shown.

[0480] T max Reported as median (min-max).

[0481] AUC inf = Area under the concentration-time curve extrapolated to infinity; AUClast = AUC from time 0 to the last (day 1) quantifiable concentration; AUC tau = area under the concentration-time curve from time 0 to 12 hours; %CV = coefficient of variation; C max = maximum observed concentration; SD = standard deviation; t 1 / 2 = terminal half-life; T max = time to reach maximum observed concentration Table 3. Statistical evaluation of the effects of probenecid on plasma pharmacokinetic parameters (pharmacokinetic population).

[0482] 1 Shows the number of subjects exposed to each treatment used in the linear model.

[0483] AUC tau = area under the concentration-time curve from time 0 to 12 hours; CI = confidence interval; C max = Maximum observed concentration; GM = geometric mean; GM = ratio of geometric means A phase 1, randomized, investigator-blind, subject-blind, sponsor-open, placebo-controlled, single-dose and multiple-dose study of compound III-2b was further conducted. There were 6 planned subject groups. Each group planned to enroll 12 subjects, for a total of 72 planned subjects. Subjects in the multi-dose group were dosed for 10 days; new subjects were recruited for each group. The results of the second and third groups provided in Table 4 are provided below. On days 1-9, subjects in these groups were dosed BID (12-hour intervals) at approximately 0800 hours and 2000 hours. On day 10, subjects were dosed only once at approximately 0800 hours. Blood samples were obtained at predetermined intervals to characterize pharmacokinetics.

[0484] Table 4. Plasma pharmacokinetic parameters following administration of Compound III-2b with and without probenecid.

[0485] a Geometric mean (%CV): for AUC inf , AUC tau , C max and CL / R; Arithmetic mean (%CV): for t1 / 2, AE%; Median (range): for T max 、T last , TAMIC1 and TAMIC2.

[0486] AE 24= the amount of unchanged thiopentane excreted in urine over 24 hours after dosing, AE% = the percentage of thiopentane dose excreted in urine, AUC inf = Area under the concentration-time curve from time 0 to time infinity, AUC tau = from time 0 to time τ The area under the concentration-time curve (dosing interval), BID = twice daily, CL / R = renal clearance, C max = maximum (peak) observed drug concentration after a single dose, C trough = minimum (trough) observed drug concentration, MIC 0.5 = duration of plasma concentration above 0.5 μg / mL, MIC 1.0 = time above the duration of a plasma concentration of more than 1.0 μg / mL, N = number of subjects; n = number of subjects contributing to the mean, NC = summary statistics not calculated, Rac = accumulation ratio, t1 / 2 = elimination half-life, TAMIC1 = time above the minimum inhibitory concentration when the minimum concentration is 0.5 μg / mL, TAMIC2 = time above the minimum inhibitory concentration when the minimum concentration is 1.0 μg / mL, T max = time to peak or maximum concentration after administration of a drug Example 2: Comparison of the effects of probenecid on plasma pharmacokinetic parameters of β-lactam compounds by oral administration and continuous infusion.

[0487] The pharmacokinetics of compound III-2b were studied in a randomized, subject-blind, investigator-open and sponsor-open, placebo-controlled, multiple-dose study, run in parallel groups. There were 7 groups, each with about 10 subjects (4:1 active agent: placebo). Subjects were administered BID (every 12 hours) for 6 days, and they were only administered once on the 7th day. Blood samples were obtained at predetermined intervals to characterize pharmacokinetics. The results are provided in Table 5.

[0488] Table 5. Geometric Means (CV%) of Plasma Pharmacokinetic Parameters—Oral Dosing.

[0489] a Median (range).

[0490] b Arithmetic mean (CV%).

[0491] c Collected only for Cohort 1 and Cohort 2.

[0492] dThe ratio was adjusted for the MW difference between thiopenem (MW = 349.45) and compound III-2b (MW = 477.62).

[0493] The first group was fed with compound III-2b 1 g BID.

[0494] The second group was in the fasting state, compound III-2b 1 g BID.

[0495] The third group was in the fed state, compound III-2b 1.5g BID.

[0496] The fourth group was in the fasting state, compound III-2b 0.5g BID.

[0497] The sixth group was given compound III-2b 1 g plus probenecid 1 g BID in the fasting state.

[0498] The seventh group was fed with compound III-2b 1 g TID.

[0499] N = total number of subjects in treatment group in indicated population. n = number of subjects with estimable AUC inf and the number of subjects with t1 / 2. CV = coefficient of variation; C max = maximum observed plasma concentration during the dosing interval; AUC inf = Area under the plasma concentration-time curve extrapolated from time 0 to time infinity; AUC last = the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration; T max = reach C max time; t1 / 2 = elimination half-life; TAMIC 0.5 = duration of plasma drug concentration exceeding 0.5 μg / mL; TAMIC 1.0 = duration of plasma drug concentration exceeding 1.0 μg / mL; R ac = cumulative ratio; Ae24 = amount of unchanged drug excreted in urine over 24 hours after dosing; Ae24% = cumulative amount of unchanged drug recovered in urine up to 24 hours after dosing, expressed as a percentage of the administered record; CL r =renal clearance; BID=twice daily; TID=thrice daily; MW=molecular weight.

[0500] The pharmacokinetics of intravenously delivered thiopentam was studied in a randomized, investigator-blind, subject-blind, sponsor-open, placebo-controlled, multiple-dose study of thiopentam. There were 5 groups dosed. Each subject was dosed for up to 14 days. Each group consisted of 10 subjects. Blood samples were obtained at predetermined intervals to characterize the pharmacokinetics. The structures are provided in Table 6.

[0501] Table 6. Geometric Means (CV%) of Plasma Pharmacokinetic Parameters—Continuous Infusion.

[0502] a The pharmacokinetic parameters are defined in Tables 1-5.

[0503] b Median [range] c Arithmetic mean [(CV%)] BID = twice daily, h = hour, CV = coefficient of variation, NE = not estimated, study stopped prior to Day 14 assessment, TAMIC0.5 = duration of plasma thiopenem concentrations exceeding 0.5 μg / mL, TAMIC1.0 = duration of plasma thiopenem concentrations exceeding 1.0 μg / mL.

[0504] Example 3: Summary of various studies in Examples 1 and 2.

[0505] The results of the various studies described in Examples 1 and 2 are summarized in Tables 7A-7C below, which are further summarized in Figure 1 It was observed that when compound III-1b or compound III-2b was administered alone by the oral route, the AUC of thiopenem on day 7 was lower than the AUC on day 1. In addition, it was observed that when compound III-1b or compound III-2b was co-administered with probenecid, the AUC of thiopenem on day 7 increased, exceeding the AUC observed on day 1.

[0506] Table 7A. Plasma pharmacokinetic parameters following administration of Compound III-1b or Compound III-2b with and without probenecid (based on Table 1 and Table 3 in Example 1).

[0507] AUC tau = Area under the concentration-time curve from time 0 to 12 hours.

[0508] Table 7B. Plasma pharmacokinetic parameters following administration of Compound III-2b with and without probenecid (based on Table 4 of Example 1).

[0509] AUC tau = Area under the concentration-time curve from time 0 to 12 hours.

[0510] Table 7C. Plasma pharmacokinetic parameters following administration of various doses of Compound III-2b with and without probenecid (based on Table 5 in Example 2).

[0511] AUC inf = Area under the concentration-time curve extrapolated to infinity.

[0512] Example 4: Effects of a β-lactam compound and probenecid given by the same route of administration.

[0513] In two separate studies, normal and healthy subjects were administered a β-lactam compound (Compound III-2b; thiopenem etzadroxil) and probenecid. In Study No. 1, subjects were administered 500 mg of thiopenem etzadroxil (as a powder for oral suspension) and simultaneously administered 500 mg of probenecid (provided as a monolayer tablet). In Study No. 2, subjects were administered 500 mg of thiopenem etzadroxil and 500 mg of probenecid in an oral co-formulation. The results of both studies are shown in Figure 2-5 and Table 8 below.

[0514] Table 8. Comparison of AUC in Subjects Given Etzadrolxil and Probenecid It was observed that administration of thiopenem etzadroxil and probenecid in a co-formulation resulted in an increase in the amount of thiopenem in the blood relative to administration of each agent in separate formulations.

[0515] Administration of the combination of thiopenem etzadroxil and probenecid in a co-formulation in the fasting state resulted in a 17.9% increase in the amount of thiopenem in the blood, as measured by the area under the curve, relative to the same amount of thiopenem etzadroxil delivered as a powder in a bottle administered together with probenecid in a monolayer tablet.

[0516] Similarly, administration of the combination of thiopenem etzadroxil and probenecid in a co-formulation in the fed state resulted in an 11.3% increase in the amount of thiopenem in the blood, as measured by the area under the curve, relative to the same amount of thiopenem etzadroxil delivered as a powder in a bottle administered with probenecid in a monolayer tablet.

[0517] Equivalent It should be understood that the present invention may be embodied in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the above-described embodiments should be considered illustrative in all respects, rather than limiting the invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the foregoing description, and all changes within the meaning and scope of the equivalent schemes of the claims are intended to be included therein.

Claims

1. Use of a combination of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof, wherein an oral co-formulation is administered simultaneously twice daily over a period of more than 24 hours, the oral co-formulation comprising 400 mg to 600 mg of the β-lactam compound or a pharmaceutically acceptable salt thereof and 400 mg to 600 mg of probenecid or a pharmaceutically acceptable salt thereof, wherein the β-lactam compound is: or a pharmaceutically acceptable salt thereof; and The disease is uncomplicated urinary tract infection, complicated urinary tract infection, complicated intra-abdominal infection, pneumonia, otitis media, sinusitis, gonococcal urethritis, pelvic inflammatory disease, prostatitis, bone infection, joint infection, diabetic foot infection or infectious diarrhea.

2. The use according to claim 1, wherein a tablet comprising the β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof is administered.

3. The use of claim 1, wherein the administration results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration.

4. The use of claim 1, wherein the administration results in a higher area under the curve (AUC) for the plasma concentration of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration, the area under the curve being 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 40% or more, 50% or more, 60% or more, 80% or more, 100% or more, 150% or more, 200% or more, 300% or more, 400% or more, or 500% or more within 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 18 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days from the administration.

5. The use of claim 1, wherein said administration results in a higher area under the curve (AUC) for the plasma concentration of said β-lactam compound in said subject in need thereof compared to comparable subjects administered said β-lactam compound and probenecid by a different route of administration, said area under the curve being 20% ​​or more higher within 1 day from said administration.

6. The use of claim 1, wherein the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) is 50% to 150%, 60% to 140%, 70% to 130%, 80% to 120%, 90% to 110%, 95% to 105%, or 98% to 102%.

7. The use of claim 1, wherein the administration results in a maximum plasma concentration (C ) of the β-lactam compound in the subject in need thereof compared to a comparable subject administered the β-lactam compound and probenecid by a different route of administration. max ) are basically the same.

8. The use of claim 1, wherein the administration results in a plasma concentration of the β-lactam compound having: a higher area under the curve (AUC) in said subject in need thereof compared to comparable subjects administered said beta-lactam compound and probenecid by a different route of administration, said area under the curve being 20% ​​or more higher within 1 day from said administration; and Substantially the same maximum plasma concentration (C ) in the subject in need thereof compared to comparable subjects administered the β-lactam compound and probenecid by a different route of administration. max ).

9. The use of claim 1, wherein 500 mg of the β-lactam compound or the pharmaceutically acceptable salt and 500 mg of probenecid or the pharmaceutically acceptable salt are administered to the subject in need thereof, and the administration results in a plasma concentration of the β-lactam compound having: an area under the curve (AUC) of 4100 ng·h / mL to 5500 ng·h / mL, 4200 ng·h / mL to 5400 ng·h / mL, 4300 ng·h / mL to 5300 ng·h / mL, 4400 ng·h / mL to 5200 ng·h / mL, 4500 ng·h / mL to 5100 ng·h / mL, 4650 ng·h / mL to 5000 ng·h / mL, 4750 ng·h / mL to 4900 ng·h / mL, or 4800 ng·h / mL to 4850 ng·h / mL within 12 hours from the administration; and The maximum plasma concentration (C) is 1100 ng / mL to 2500 ng / mL, 1200 ng / mL to 2400 ng / mL, 1300 ng / mL to 2300 ng / mL, 1400 ng / mL to 2200 ng / mL, 1500 ng / mL to 2100 ng / mL, 1650 ng / mL to 2000 ng / mL, 1750 ng / mL to 1900 ng / mL, or 1800 ng / mL to 1850 ng / mL. max ).

10. The use of claim 1, wherein 500 mg of the β-lactam compound or the pharmaceutically acceptable salt and 500 mg of probenecid or the pharmaceutically acceptable salt are administered to the subject in need thereof, and the administration results in a plasma concentration of the β-lactam compound having: within 12 hours from the administration, an area under the curve (AUC) of 7000 ng·h / mL to 8400 ng·h / mL, 7100 ng·h / mL to 8300 ng·h / mL, 7200 ng·h / mL to 8200 ng·h / mL, 7300 ng·h / mL to 5100 ng·h / mL, 7450 ng·h / mL to 8100 ng·h / mL, 7500 ng·h / mL to 8050 ng·h / mL, or 7550 ng·h / mL to 8000 ng·h / mL; and The maximum plasma concentration (C) is between 2100 ng / mL and 3300 ng / mL, between 2200 ng / mL and 3200 ng / mL, between 2300 ng / mL and 3100 ng / mL, between 2400 ng / mL and 3000 ng / mL, between 2500 ng / mL and 2900 ng / mL, between 2550 ng / mL and 2800 ng / mL, between 2600 ng / mL and 2750 ng / mL, or between 2650 ng / mL and 2700 ng / mL. max ).

Citation Information

Patent Citations

  • Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides

    US4522811A

  • Method and apparatus for producing position addressable combinatorial libraries

    US5763263A

  • Penem prodrugs

    CN101479279A